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Glioblastoma multiforme (GBM) is the most common and aggressive primary brain
tumor with poor prognosis due in part to drug resistance and high incidence of tumor
recurrence. The drug resistant and cancer recurrence phenotype may be ascribed to the
presence of glioblastoma stem cells (GSCs), which seem to reside in special stem-cell niches
in vivo and require special culture conditions including certain growth factors and serumfree medium to maintain their stemness in vitro. Exposure of GSCs to fetal bovine serum
(FBS) can cause their differentiation, the underlying mechanism of which remains unknown.
Reactive oxygen species (ROS) play an important role in normal stem cell differentiation,
but their role in affecting cancer stem cell fate remains unclear. Whether the metabolic
characteristics of GSCs are different from other glioblastoma cells and can be targeted are
also unknown.
vi

In this study, we used several stem-like glioblastoma cell lines derived from clinical
tissues by typical neurosphere culture system or orthotopic xenografts, and showed that
addition of fetal bovine serum to the medium induced an increase of ROS, leading to
aberrant differentiation and decreases of stem cell markers such as CD133. We found that
exposure of GSCs to serum induced their differentiation through activation of mitochondrial
respiration, leading to an increase in superoxide (O2-) generation and a profound ROS stress
response manifested by upregulation of oxidative stress response pathway. This increase in
mitochondrial ROS led to a down-regulation of molecules including SOX2, and Olig2, and
Notch1 that are important for stem cell function and an upregulation of mitochondrial
superoxide dismutase SOD2 that converts O2- to H2O2. Neutralization of ROS by antioxidant
N-acetyl-cysteine in the serum-treated GSCs suppressed the increase of superoxide and
partially rescued the expression of SOX2, Olig2, and Notch1, and prevented the seruminduced differentiation phenotype. Additionally, GSCs showed high dependence on
glycolysis for energy production. The combination of a glycolytic inhibitor 3-BrOP and a
chemotherapeutic agent BCNU depleted cellular ATP and inhibited the repair of BCNUinduced DNA damage, achieving strikingly synergistic killing effects in drug resistant GSCs.
This study uncovers the metabolic properties of glioblastoma stem cells and suggests
that mitochondrial function and cellular redox status may profoundly affect the fates of
glioblastoma stem cells via a ROS-mediated mechanism, and that the active glycolytic
metabolism in cancer stem cells may provide a biochemical basis for developing novel
therapeutic strategies to effectively eliminate GSCs.
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CHAPTER 1
INTRODUCTION
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1. CANCER STEM CELL
Cancer stem cells (CSCs) are a sub-population of rare malignant cells which have a
capability for indefinite proliferation, continuous self-renewal and multi-lineage
differentiation (1). Although the existence of CSCs was first proposed over fifty years ago
(2), only in the last two decades have these cells been discovered in hematological
malignancies. Leukemia stem cells (LSCs) have been identified in both mice and patients
with acute myeloid leukemia (AML) (3, 4). CD34+ CD38- AML cells can engraft severe
combined immune-deficient (SCID) mice to produce large numbers of colony-forming
progenitors; however, CD34+ CD38+ and CD34- AML cells don’t have this property (5).
Since then, CD34+CD38- have been utilized as markers for enriching LSCs (3). Other stem
cell markers including CD123+ (6) and Hoechst33342low (7) are also identified in AML.
Additionally, CSCs have been identified in solid tumors of breast and brain. CD44+CD24/low

Lineage- breast cancer cells and CD133+ brain tumor cells can self-renew and

differentiate to produce a phenotype identical to the initial tumor (8, 9). A large quantity of
recent studies have also indicated the existence of CSCs in different types of solid tumors
(10, 11) such as colon (12), pancreatic (13), prostate (14), and liver cancer (15). A number
of cell surface markers including prominin-1 (CD133), CD44, aldehyde dehydrogenase 1
(ALDH1), epithelial-specific antigen (ESA) and a fluorescent dye Hoechst33342 have been
proven useful for isolating CSCs (Table 1) (11).
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Table 1. Cancer stem cell markers in different tumors.
Cancer Type

Markers

References

Brain Tumor

CD133+, Nestin+, Hoechst33342 exclusion

(9, 16, 17)

Breast Cancer

CD44+CD24-/low, Oct4+, CX43-, ALDH1+

(8, 18-20)

Acute Myeloid Leukemia

CD34+CD38-, CD123+, Hoechst33342 exclusion

(3, 6, 7)

Multiple Myeloma

CD138-,CD19+

(21, 22)

Colon Cancer

CD133+, ESAhi/CD44+, ALDH1+

(12, 23, 24)

Prostate Cancer

CD133+

(25)

Hepatic Cancer

CD133+, CD90+

(26)

Lung Cancer

CD133+ , Hoechst33342 exclusion

(27, 28)

Head & Neck Cancer

CD44+

(29)

Pancreatic Cancer

CD44+CD24+ ESA+, CD133+CXCR4+

(13, 17, 30)

Melanoma

ABCB5+

(31)

Ovarian Cancer

CD44+CD177+, Hoechst33342 exclusion

(32, 33)

3

There is growing evidence indicating that CSCs are crucial to tumor initiation and
maintenance, while the origin of CSCs remains elusive. Since CSCs display normal stem
cell features: the ability to self-renew and differentiate, either tissue stem cells or bone
marrow stem cells have been identified as the cells of origin for cancer. Barker et al have
shown that Apc deletion in long-lived intestinal stem cells (Lgr5+) led to malignant
transformation (34). Oncogenic K-ras transformation or p53 mutation can stimulate
bronchioalveolar stem cell expansion, which is related to lung adenocarcinoma initiation (35,
36). In addition, bone marrow stem cells can be recruited into stomach and give rise to
gastric cancer under chronic infection of Helicobacter pylori (37). However, a number of
studies suggest that malignant tumors can be initiated in differentiated cells. Not only neural
stem cells (NSCs) but also astrocytes can be induced into glioma by combined loss of p16
(INK4a) and p19 (ARF) (38, 39). But neurofibromin deficiency only cause tumor in
differentiated glia cells instead of neural crest stem cells (40). It remains controversial
whether CSCs origin from normal stems cells or differentiated cells. They may rise from
normal stem cells or progenitor cells through mutations or they may be derived from
differentiated cells through dedifferentiation (41, 42).
Although CSCs may constitute a small fraction of the total cancer cells in the tumor
bulk, this special subpopulation is thought to play a major role in cancer resistance to
chemotherapy and radiotherapy, leading to persistence of residual disease and cancer
recurrence (43). This phenomenon is due in part to the unique biological properties of CSCs
including high capacity of DNA repair, high expression of certain ATP-dependent drug
exporting pumps, high levels of glutathione synthesis, and high expression of cell survival
factors (44-46). On one hand, CSCs preferentially activate the DNA damage checkpoint
4

response after radiation that can repair radiation induced DNA damage more efficiently than
non-CSCs (47). On the other hand, CSCs can pump out many chemotherapeutic agents
through ATP-binding cassette (ABC) transporters, which contribute to their chemotherapy
resistance (48). Additionally, compared to non-CSCs, CSCs show a significant
overexpression of glutathione synthesis enzymes that might be responsible for
chemotherapy and radiation resistance (46, 49).
A detailed understanding of the factors that affect the ability of CSCs to maintain
their stemness is important for the development of new strategies to effectively eliminate
cancer stem cells or to induce their differentiation. Nevertheless, there are very limited
therapeutic strategies that are effective in eliminating CSCs currently, keeping CSCs a major
challenge in cancer treatment.
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GLIOBLASTOMA STEM CELL

Glioblastoma multiforme (GBM), a WHO grade IV astrocytoma, is the most
common and aggressive primary brain tumor in adults. Although maximal surgical resection,
radiotherapy, and chemotherapy are performed in patients with this brain cancer, the
treatment outcomes are still unsatisfactory, with median survival durations of only 12-15
months and the 5-year survival rates of less than 10% (50, 51). Previous studies
demonstrated that glioblastoma stem cells (GSCs) promote chemoresistance and
radioresistance, which are likely responsible for the recurrence of GBM (47, 52-54). Several
markers have been identified for isolating GSCs, among which CD133 is the most widely
used one. CD133, a cell surface glycoprotein containing five trans-membrane domains and
two glycosylated extracellular loops, was first identified in hematopoietic stem cells (55).
High levels of CD133 expression have been found in various stem and progenitor cell
populations including GBM. CD133+ subpopulation of brain tumor cells have CSC
properties (9) and only these cells but not the CD133- cells are capable of tumor initiation
when inoculated into nonobese diabetic/severe combined immunodeficiency (NOD/SCID)
mouse brains (56). Another CSC marker Hoechst 33342, a fluorescent DNA binding dye,
was also applied to GBM (57, 58). The GSCs are isolated as the side population based on
the ability of cells to pump out Hoechst 33342 through the verapamil-sensitive ATP binding
cassette transporter (59). However, all of these GSC markers were challenged by some
studies. CD133-negative glioblastoma cells are also able to initiate tumors (60, 61) and side
population is not necessary for identifying GSCs (62).
Long-term expansion of GSCs has been possible in neural sphere culture which was
previously established for isolating neural stem cells and progenitor cells (63). The neural
6

sphere culture contains no serum and is supplemented with growth factors EGF and FGF2,
and additional mitogens or antioxidants. This serum-free culture system is successful to
isolate GSCs with long term self-renewal and tumorigenic potential (64, 65), and it closely
mimics the phenotype and genotype of parental GBM than serum-containing culture (66).
However, adding serum into the neural sphere culture can cause irreversible differentiation
of neural stem cells (67, 68).
Like other CSCs, GSCs have been found to be resistant to all kinds of treatments.
GSCs display a marked resistance to commonly used chemotherapeutic agents and are able
to recover and proliferate after drug treatment (69). GSCs can also be enriched after
radiation or in recurrent GBM when compared with primary GBM, which might be
attributed to GSCs’ efficient activation of the DNA damage response (70, 71). Additionally,
recent studies have suggested that hypoxic environment play critical roles in the
maintenance of GSC population (72-74). The hypoxic niches may further promote drug
resistance, which makes targeting GSCs more difficult. Some novel compounds have been
found to be effective to kill GSCs including debromohymenialdisine, an inhibitor of
checkpoint kinases, which can reverse the radioresistance of GSCs (70) and cyclopamine, a
Hedgehog pathway inhibitor, which can decrease GSCs and block tumor formation (75).
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MICROENVERIONMENT

Normal stem cells reside in some physiologically limited and specialized
microenvironment, which is named stem cell niche (76). The stem cell niche is the sum of
all cell-cell and cell-extracellular matrix interactions and controls normal asymmetrical
division of stem cells by maintaining a balance between self-renewal and differentiation.
Brain stem cells reside in the vascular rich subventricular zone and subgranular layer (77).
It’s likely that vascular-derived factors including brain-derived neurotrophic factor (BDNF),
vascular endothelial growth factor C (VEGFC) and pigment epithelium-derived factor can
regulate neural stem cell function (78). Other cell types such as ependymal and transit
progenitor cells are also likely to regulate NSCs. The interaction of NSCs and their niche is
not unidirectional. NSCs may modulate the stem cell niche and induce angiogenesis by
increasing the expression of VEGF and BDNF in endothelial cells (79).
Recently, a CSC niche that has a similar role as normal stem cell niche has been
proposed (80) and supported by emerging evidence. Like normal stem cells, CSCs depend
on a permissive microenvironment to retain their self-renewal abilities and give rise to more
differentiated cells (81). CSCs seem to reside in a hypoxic niche due to aberrant blood
vessel formation and rapid cell growth (82). Hypoxia has been found to functionally
promote the self-renewal ability of GSCs (73) and increase the expression of CD133 (83)
and side population signature genes in glioblastoma cell lines (84, 85). These effects of
hypoxia are likely mediated by HIF-1α or HIF-2 (84, 85). Knocking down HIF1α or HIF2α
can not only lead to reduced cell growth and survival in GSCs in vitro but also result in
decreased tumorigenic capacity and increased survival of mice in vivo (86).
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Stem cells of brain tumors including GBM have been found within vascular niches
and the relationship between CSCs and endothelial cell is reciprocal (Figure 1). On one hand,
the vascular endothelial cells can maintain brain tumor cells in a stem-like state and
accelerate the tumor initiation and growth when co-transplanted in mice brain (87).
Endothelial cells directly provide Notch ligands (88) or release nitric oxide to neighboring
CSCs (89), activating the Notch pathway in CSCs. On the other hand, CSC can promote the
endothelial cell growth and vessel formation. CD133+ glioma stem cells, but not CD133glioma cells, cause highly proliferative and angiogenic tumors when implanted into mice
brains, and they also secret 10 to 20 folds more VEGF than CD133- glioma cells in vitro
(70). Treating CD133+ glioblastoma cells with a VEGF antibody, bevacizumab which binds
to VEGF-A ligand to prevent endothelial cell receptor activation, can inhibit their
proangiogenic effects on endothelial cell (migration and tube formation) and initiate tumors
in xenografts (70).

9

Figure 1. Glioblastoma stem cells reside within a hypoxia and perivascular
niche. The GSC niche is composed of tumor blood vessels, stromal cells and
extracellular matrix. GSCs remain quiescent in hypoxic niches, but create
vascular niches in order to proliferate. On one hand, GSCs stimulate the
growth of neovasculature by expressing growth factors such as VEGF. On the
other hand, tumor blood vessels create a vascular niche to help maintain GSCs.
GF: growth factors; GSC: glioblastoma stem cell; OGC: other glioblastoma
cell; SC: stromal cell; TBV: tumor blood vessels.
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ABERRANT DIFFERENTIATION

Glioblastoma grown from cancer stem cells contains mixed populations of cancer
stem cell, progenitor cell and heterogeneous cell types. Besides self-renewal, GSCs can be
induced to differentiate into all neuronal lineages expressing the markers of neuronal,
astroglial or oligodendroglial cells (90). GSCs are also able to differentiate into functional
endothelial cells in vivo (91). Since the differentiation of GSCs is not tightly regulated like
in NSCs, it’s difficult to categorize glioblastoma cells according to the hierarchical pyramid
of normal development (90). However, most of studies have applied the markers based
differentiation criteria of NSCs to GSCs.
Fetal bovine serum (FBS) or all-trans-retinoic acid (ATRA) treatment can rapidly
cause GSC morphology change, dramatically decrease NSC markers and induce lineagespecific differentiation markers (92, 93). Culturing under serum condition results in a loss of
NSC markers, a gain of glial or neuronal markers, and a decrease of tumorigenicity (94).
ATRA which has been proven to be a powerful antitumor agent in acute promyelocytic
leukemia can induce differentiation and cell death in GSCs (94, 95). It can also inhibit the
tumor growth in xenograft mice, which is likely mediated by Notch pathway (92).
Interference with other molecules or pathways is also able to induce differentiation. For
instance, inhibition of Bmi1 and glycogen synthase kinase 3 beta (GSK3β) activity increases
differentiation markers and reduces colony formation in glioblastoma cells (96).
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2. REACTIVE OXYGEN SPECIES
Reactive oxygen species (ROS) are a group of highly reactive oxygen-containing
species that include superoxide (O2-), singlet oxygen (1O2), hydrogen peroxide (H2O2) and
the hydroxyl free radical (.OH) (97). ROS production is a cascade of reactions that usually
begins with the generation of superoxide (98). Mitochondrial electron transport chain (ETC),
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) complex, and
the endoplasmic reticulum (ER) system have been recognized as major generators of cellular
ROS (Figure 2). Mitochondrial ETC produces O2- as a by-product of cellular metabolic
pathway through passing electrons to O2 (99). Among the five components of ETC, complex
I and complex III are the major sites for ROS formation (99). Another major source of
cellular ROS is the NOX, a membrane-bound enzyme complex, that generates superoxide
by transferring electrons from NADPH to O2 (100). The other primary generator for ROS is
the ER, which is overcrowded with a number of enzymes (NOX, flavin monooxygenases,
gulonolactone oxidase and cytochrome P450 isoenzymes) that can produce superoxide or
hydrogen peroxide as by-products of the reactions (101-104).
Because ROS interact non-specifically with lipids, proteins and nucleic acids,
causing lipid peroxidation, protein oxidation and DNA mutations, respectively (105), they
were initially considered to be harmful. Later studies found that ROS also play an important
role in cell proliferation, apoptosis and signaling (Figure 3) (100). ROS have a multitude of
effects on cell cycle progression, of which depends upon the amount of ROS, the type of
ROS, and the duration of exposure of the cells to ROS (106). A short exposure of nonproliferating cells to moderate ROS may stimulate proliferation. Prolonged exposure to low
ROS results in differentiation. For instance, ROS generated from complex III is required to
12

initiate the differentiation of human mesencymal stem cells into adipocytes. Disruption of a
bHLH transcription factor, UPB1, which directly regulates the expression of a set of
antioxidant enzymes peroxidases, leads to a delay in the onset of differentiation (107). If the
amounts of ROS are high or the exposure to ROS is long, cells will arrest in all phases and
undergo apoptosis (106). ROS increase induces the expression of cyclin kinase inhibitor p21,
the inhibition of CDK2, the expression of Chk1 and the decrease of Cdc25c, which lead to
subsequent G1 phase, S phase and G2/M phase arrest respectively (106). Besides its role in
cell cycle progression, ROS also performs as intracellular messengers and affect different
transcription factors and intracellular signaling pathways (100). Low levels of ROS induce
Nrf2, a transcription factor coding for the antioxidant enzymes (108). Intermediate amount
of ROS triggers the activation of two transcription factors, nuclear factor-ĸB (NF-ĸB) and
activator protein (AP)-1 (109). H2O2 can activate NF-ĸB, making it dissociate from IĸB and
translocate to the nucleus (110). H2O2 can also upregulates AP-1 activity through ERKs,
JNKs and p38 (111). ROS can also participate in signal transduction pathways through
activating mitogen-activated protein kinases (MAPK) pathway (112) and Janus kinase/signal
transducers and activators of transcription (JAK/STAT) pathway (113). However, high
amount of ROS induces opening of the mitochondrial permeability transition pore, leading
to apoptosis (114).
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Figure 2. Major sources of cellular ROS. Mitochondrial electron transport
chain, NADPH oxidase (NOX) complex, and the endoplasmic reticulum (ER)
system are primary generators for ROS.
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Figure 3. ROS levels and cell status. Quiescent cells maintain low
levels of ROS. An intermediate increase of ROS induces Nrf-2, NF-ĸB
and AP-1 signaling, and triggers cell proliferation. A high amount of
ROS induces perturbation of mitochondrial permeability transition pore
(Mito PT pore), leading to apoptosis or necrosis.
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ROS IN CANCER
ROS may be a driving force for cancer initiation and progression. DNA damage and
mutation caused by ROS are considered as a major cause of cancer (115). Most of ROSinduced mutations seem to involve modification of guanine, causing G→T transversions
(116-118). If oncogenes or tumor suppressor genes are related, the mutation can result in
cancer initiation or progression (115). As an evidence, extensive oxidative modifications in
DNA has been observed in cancers (119), in which the hydroxylation of guanine in the 8position (8-OHdG) is the most frequent and most mutagenic lesion. Cigarette smoke can
cause the accumulation of 8-OHdG, which causes lack of base pairing specificity and
misreading of the modified base and adjacent residues, thus leading to breast cancer and
liver cancer (115). Sustained ROS may also trigger epithelial–mesenchymal transition
(EMT), invasion and migration in cancer cells (120). Repeated treatment with a low dose of
H2O2 in mammary epithelial cells results in EMT like morphology transformation and
invasiveness (121). ROS can also induce urokinase plasminogen activator receptor
expression and stimulate gastric cancer cell invasiveness and metastasis (122).
Compared with normal cells, cancer cells have shown increased levels of ROS (123125). ROS generation is induced after the expression of several oncogenes including H-Ras
and c-Met (126-128). The mitochondrial DNA with mutations from highly metastatic tumor
cell line can confer high metastatic potential to poorly metastatic cell line, which is likely
mediated by ROS overproduction and can be blocked by a ROS scavenger N-acetylcysteine
(NAC) (129). Since cancer cells have shown increased ROS status, further increasing ROS
may make them more vulnerable to the damage than normal cells (130). Compounds which
promote ROS generation in cancer cells have shown promising anticancer activities.
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Elesclomol, a compound that increases ROS production, has shown therapeutic activity in
melanoma (130). Other compounds which interfere with the antioxidant, glutathione have
also shown effectiveness in cancer therapy. Both phenethyl isothiocyanate (PEITC) and
buthionine sulphoximine (BSO) can lead to a decrease of cellular GSH, causing cancer cell
death (131, 132).
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ANTIOXIDANT SYSTEM
Cells are capable of keeping themselves in an oxidation-reduction reactions (redox)
homeostasis state because of several antioxidant defenses including ROS-scavenging
enzymes and small scavenger molecules (133). There are three major intracellular ROSscavenging enzymes: superoxide dismutases (SOD), catalases and peroxidases (Figure 4).
The SODs that convert superoxide to hydrogen peroxide are the first and most important
line of antioxidant enzymes against ROS (134). Three distinct isoforms of SOD have been
identified in mammals: SOD1 (CuZn-SOD), SOD2 (Mn-SOD), and SOD3 (Ec-SOD) (135).
The primary locations of SOD1, SOD2 and SOD3 are cytoplasm, mitochondria and outside
of cytoplasm respectively. Catalases and peroxidases catalyze the reaction of hydrogen
peroxide into water.

Peroxidases include glutathione peroxidase (GPX), peroxiredoxin

(PRX), thioredoxin (TRX), thioredoxin reductase (TR), glutaredoxin (GRX), sulfiredoxin
and sestrin. GPx is the most prominent of them.
The intracellular non-enzymatic antioxidants are composed of vitamins like vitamin
C, vitamin E, proteins like β-carotene, albumin and GSH (136). GSH is present in
millimolar concentrations in cells and is the major component in maintaining redox
homeostasis. GSH is synthesized by two enzymes, γ-glutamylcysteine synthetase (γ-GCS),
which is the rate-limiting enzyme, and glutathione synthetase (137).
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Figure 4. Three major ROS-scavenging enzymes in cells: superoxide
dismutases (SOD), catalases and peroxidases. SOD, superoxide dismutases;
CAT, catalase; TRX, thioredoxin; GRX, glutaredoxin; PRX, peroxiredoxin; GPx,
glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; GSSG,
oxidized glutathione; G6PDH, glucose-6 phosphate dehydrogenase.
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Nuclear factor E2-related factor 2 (Nrf2), a basic leucine zipper transcription factor
that controls the genes coding for antioxidant enzymes, plays a crucial role in protecting
cells against oxidative stress. Phosphorylation of Nrf2 at Serine-40 by protein kinase C was
reported to trigger its nuclear translocation that is likely a critical signaling event leading to
antioxidant response element (ARE)-mediated cellular antioxidant response (138). Nrf2
forms a heterodimer with musculoaponeurotic fibrosarcoma oncogene homolog, thereby
binding to ARE to regulate the basal and inducible expression of more than 200 genes
including antioxidant genes (139). Classic Nrf2-target genes includes SOD, glutathione Stransferase (GST), NAD(P)H: quinone oxidoreductase (NQO)1, NQO2, γ-GCS, glutamate
cysteine ligase (GCL), GPx, TRX, TrxR, PRX, and heme oxygenase 1 (HO-1) (139). An
important negative regulator of Nrf2 is a cytosolic protein Keap1. Under normal conditions,
Keap1 binds with Nrf2 leading to its proteasomal degradation (140). ROS cause dissociation
of Nrf2 from Keap1, leading to its translocation to the nucleus, which activates ARE, thus
up-regulates a lot of ROS scavenging enzymes.
Forkhead box class O (FoxO) family are also critical regulators of oxidative stress
and exert this function at least partially by modulating the expression of several antioxidant
enzymes (141). Oxidative stress activates FoxOs via phosphorylation by the Jun N-terminal
kinase (JNK), which increases the expression of SOD2 and catalase (142).
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ROS IN STEM CELLS
ROS are known to play a role in affecting the fates of normal stem cells (143). Stem
cells were thought to maintain low levels of ROS. Elevated ROS has been observed to
induce differentiation of embryonic stem cells into cardiovascular and mesendodermal cells
(144, 145). NSCs and hematopoietic stem cells (HSCs) contain lower levels of ROS than
their mature progeny, while increased ROS levels are associated with lowered self-renewal
capacity, increased cell cycling and reduced viability (146-148). Studies of genetically
manipulated mice have deepened the understanding of ROS effects on stem cells. Ataxia
telangiectasia mutated gene deficient (Atm-/-) mice display increased levels of ROS, which
lead to depletion of normal HSCs after serial transplantation (148). FoxOs are essential for
the regulation of hematopoietic stem and progenitor cells. FoxO3a knockout mice showed
elevated ROS that resulted in loss of HSC self-renewal capacity (149). PR
domaincontaining16 (Prdm16) deficiency led to increased ROS levels and depletion of
hematopoietic and neural stem cells (150). All these stem cell abnormalities can be restored
or partially rescued by treatment with antioxidants (148-150).
However, recent evidence suggests that appropriate levels of ROS are required to
promote proliferation and survival of stem and progenitor cells. AKT1/2 double-deficient
(AKT1-/-/AKT2-/-) HSC have been found to persist in the G0 phase of the cell cycle and
demonstrate decreased ROS (151). Pharmacologically increasing ROS levels promotes the
HSC proliferation and differentiation. Proliferative NSCs maintain a high ROS status and
are highly responsive to ROS stimulation (152). ROS-mediated self-renewal and
neurogenesis are dependent on PI3K/Akt pathway, and can be inhibited by NOX or PI3K
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inhibitors. Taken together, ROS is tightly controlled in normal stem cell and keeping ROS at
an appropriate level is crucial to maintaining stem cell functions.
Redox status of cancer stem cell has not been well-characterized so far. Little is
known about whether ROS regulate any signaling pathways in CSCs. CD24-/low/CD44+
breast cancer stem cells are enriched after radiation, perhaps due to lower levels of ROS in
these cells (153). It has also been found that human and murine breast cancer stem cells
contain lower cellular levels of ROS compared to the corresponding non-tumorigenic cells,
which is likely related to their high ROS-scavenging capacity (46). Human gastrointestinal
cancer stem-like cells with a high level of CD44 expression display an enhanced capacity
for glutathione synthesis and defense against ROS, probably by stabilizing a glutathione
substrate transporter xCT (154). CD44 ablation by siRNA depletes cellular glutathione and
increases ROS in cancer cells (155). It has been shown salinomycin is effective in inhibiting
prostate cancer cell including CSCs, which is probably due to the induction of ROS (156).
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3. CANCER CELL METABOLISM
Otto Warburg observed that, even in the presence of ample oxygen, cancer cells
prefer to produce energy by a high rate of glycolysis followed by lactic acid fermentation,
rather than by a comparatively low rate of glycolysis followed by oxidative phosphorylation
like most normal cells, a phenomenon known as the “Warburg effect” (157). Although the
Warburg effect has been generally accepted as a metabolic hallmark of cancer, its causal
relationship with cancer progression remains unclear (158)
Why do cancer cells that have a great need for ATP use such a low efficient way of
metabolism? Warburg proposed that cancer cells have a permanent impairment of oxidative
phosphorylation resulting in a compensatory increase of glycolysis to cope with a lack of
ATP generation (159). While later studies have found that mitochondrial defects are rare and
most tumor cells retain the capacity for oxidative metabolism (160, 161). The high
glycolytic rate provides several advantages for proliferative cancer cells as long as glucose
supplies are not limited. First, it produces ATP at a higher rate than oxidative
phosphorylation and allows cells to use the most abundant extracellular nutrient, glucose
(162). Although the yield of ATP per mol glucose consumed is low, when cancer cells are in
resource competition with normal cells that produce ATP at a lower rate but a higher yield,
they consume the resource more rapidly and have a growth advantage over normal
cells(163).

Second, aerobic glycolysis allows cancer cells for ATP production in the

absence of oxygen, which help the cancer cells proliferate in hypoxic conditions (164).
Finally, aerobic glycolysis provides a biosynthetic advantage for cancer cells by producing
intermediates for biosynthetic pathways including ribose sugars for nucleotides, glycerol and
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citrate for lipids, nonessential amino acids and NADPH. So the Warburg effect benefits both
bioenergetics and biosynthesis (162).
Not only the tumor microenvironment but also oncogene activation can drive
metabolic changes and lead to increased glucose consumption, decreased oxidative
phosphorylation, and accompanying lactate production (158). Due to the high proliferation
of cancer cells, hypoxia tends to be widespread in solid tumors. When cancer cells outgrow
the recruited endothelial cells, new disorganized blood supplies usually form and further
contribute to hypoxia. Therefore, the anaerobic use of glucose through glycolysis is required
for cancer cells survival (165). Cells transformed by the oncogenes V-Src or H-Ras display
increased expression of HIF-1 or VEGF and exhibit increased rates of aerobic glycolysis
(165). Additionally, loss of tumor suppressor p53 prevents the synthesis of cytochrome c
oxidase protein, which interferes with mitochondrial oxidative phosphorylation (158).
The dependence of cancer cells on increased glucose uptake for aerobic glycolysis
has been proven useful for tumor detection and monitoring.

[18F]fluorodeoxyglucose

positron emission tomography (FDG–PET) imaging that uses a radioactive glucose analogue
to detect regions of high glucose uptake has been widely applied in various tumor diagnosis
and evaluation (162).
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REGULATION OF CANCER CELL METABOLISM
The PI3K/Akt/mTOR pathway is a master regulator of aerobic glycolysis in cancers.
This pathway is activated by mutation in PI3K complex, mutations in tumor suppressor
genes or by aberrant signaling from receptor tyrosine kinases (162). Akt stimulates
glycolysis and increases lactate production in either nontransformed cells or cancer cells by
increasing the expression and membrane translocation of glucose transporters and by
phosphorylating key glycolytic enzymes, such as hexokinase and phosphofructokinase 2
(166, 167). The activation of this pathway also stimulates protein and lipid synthesis and cell
growth (160).
A key transcription factor hypoxia-inducible factor-1 (HIF-1) regulates glucose
metabolism under low oxygen conditions. Under normal oxygen conditions, HIF1 can be
stabilized by oncogenic pathways including PI3K and mutations in tumor suppressors such
as von Hippel–Lindau tumour suppressor (VHL), succinate dehydrogenase (SDH) and
fumarate hydratase (FH) (162). HIF-1 activation increases the transcription of genes
encoding glucose transporter and glycolytic enzymes (168). HIF-1 can also induce
expression of pyruvate dehydrogenase kinase 1 (PDK1), which inhibits the mitochondrial
pyruvate dehydrogenase (PDH) complex and reduce the entry of pyruvate into the
tricarboxylic acid (TCA) cycle and increases conversion of pyruvate to lactate (169, 170).
Another metabolic regulator of cancer cell is the oncogenic transcription factor cMyc. Overexpression of c-Myc collaborates with HIF-1 to promote glycolysis by induction
of glucose transporter and glycolytic enzymes such as hexokinase 2 and PDK1 (171, 172).
Additionally, c-Myc transformed cells require glutamine for survival and depriving these
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cells of glutamine leads to a depletion of TCA cycle intermediates. c-Myc increases
glutaminolysis which may thus generate more antioxidant glutathione for cancer cells (162).
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TARGETING CANCER CELL METABOLISM
Given that cancer cells depend on changes in metabolism to support their survival
and growth, targeting cancer cells’ metabolism has become an important area of research.
Although there have been attempts to block the glycolytic pathway in tumor cells using
compounds such as 2-deoxyglucose (2-DG) and 3-bromopyruvate (3-BrPA), effective
strategies have not been devised (173-175).

Several metabolic enzymes have been

considered as candidate targets (Figure 5), and promising results have been obtained by
using some compounds (176). Various compounds have been shown to block glucose uptake
in cancer cells, but none of them are specific glucose transport inhibitors. Glucose
transporter 1 (Glut1) and Glucose transporter 3 (Glut3) are expressed at much higher levels
in cancer cells than in normal cells, suggesting that these transporters can be possible
therapeutic targets. A competitive inhibitor of glucose, 2-deoxy-D-glucose (2-DG) is
phosphorylated by hexokinase to produce 2-deoxyglucose-6-phosphate and competes with
enzymes that metabolize glucose-6-phosphate (176). Cancer cells preferentially express
hexokinase 2 (HK2) and repression of this enzyme is likely to be toxic to cancer cells. 3BrPA is an alkylating agent that has been shown to inhibit HK2 and glyceraldehyde-3phosphate dehydrogenase (GAPDH), two key enzymes in the glycolytic pathway (173, 177).
The derivative of 3-BrPA, 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP), was
developed by our laboratory. It has similar mechanisms of action as 3-BrPA and is
chemically more stable, and has been shown to be highly potent in causing ATP depletion in
cancer cells (178). Another glycolytic enzyme preferentially expressed by cancer cells is
pyruvate kinase M2 (PKM2). Targeting PKM2 by inhibitors or shRNA can decrease cancer
cell proliferation and tumorigenicity (179, 180).
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Figure 5. Targeting metabolic enzymes in cancer. The metabolic enzymes that are
considered as therapeutic targets for cancer (shown as red in the figure). GLS,
glutaminase; GLUT, glucose transporter; IDH, isocitrate dehydrogenase; LDH, lactate
dehydrogenase; PDK, pyruvate dehydrogenase kinase; PKM2, pyruvate kinase M2
isoform.
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HYPOTHEIS AND SPECIFIC AIMS
Although cancer stem cells (CSCs) have been isolated from various types of cancer
and their microenvironment is considered to be crucial for maintaining their stemness, the
metabolic characteristics and mitochondrial function of cancer stem cells have not been well
investigated. When cultured under serum-free conditions, CSCs can maintain their selfrenewal and multi-lineage differentiation abilities; while adding serum into the culture
causes their differentiation. It remains unknown how serum induces differentiation in CSCs
and whether the metabolism differs between CSCs and other cancer cells.
I hypothesize that GSCs have low mitochondrial activity and mainly depend on
glycolysis for energy production compared with their differentiated progenies, and that such
metabolic properties can be utilized for designing new therapeutic strategies to eliminate
GSCs. Specifically, the major goals of this study are to compare the mitochondrial
respiratory function, glycolytic metabolism, and generation of reactive oxygen species in
GSCs and in the downstream progeny cells induced by differentiation factors like FBS, to
evaluate the role of glycolysis and ROS in GSCs survival and drug sensitivity, and to test
new therapeutic strategies to effectively kill the drug-resistant GSCs.
Considering the important role of CSCs in cancer development of disease recurrence,
this proposed research project is of high significance in that it will provide new insights into
cancer stem cell metabolism with potentially important therapeutic implications.
The specific aims of my thesis project are to:
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Specific Aim 1. Evaluate the role of mitochondria and ROS in mediating GSC
differentiation in response to serum induction.
Specific Aim 2. Investigate the underlying mechanisms of how serum induces GSC
differentiation.
Specific Aim 3. Design new therapeutic strategies to effectively kill GSCs based on
their metabolic properties.
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CHAPTER 2
MATERIALS AND METHODS
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Cell Lines and Cell Culture
GSC11, GSC23 and GBM3752 cell lines were isolated from three fresh surgical
specimens of glioblastoma multiforme by Dr Howard Colman and Dr Xiao-nan Li’s groups.
GSC11 and GSC23 were grown in Dulbecco's Modified Eagle Medium: Nutrient Mixture F12 (DMEM/F12) medium (Mediatech Inc; Manassas, VA) supplemented with B27
(Invitorgen; Carlsbad, CA), 20ng/ml epidermal growth factor (Miltenyi Biotec; Auburn,
CA), 20ng/ml of basic fibroblast growth factor (Miltenyi Biotec; Auburn, CA) and 2 mM Lglutamine (Mediatech Inc; Manassas, VA). GBM3752 cells came from orthotopic tumors in
murine brain, as previously described (181) and were cultured in the same supplemented
DMEM/F12 medium of GSC11 and GSC23 for less than 5 passages. Differentiation was
induced with 5% FBS (Sigma-Aldrich; St. Louis, MO). For NAC treatment, cells were
cultured under the 5% FBS containing medium with different concentrations of NAC
(Sigma-Aldrich). The glioma cell line U87 and non-malignant human astrocytes (NHAs)
were maintained in DMEM (Mediatech) supplemented with 10% FBS. Cells were cultured
in a humidified incubator maintained at 37°C with 5% CO2 for 20 to 45 passages. Cells were
treated with accutase (Sigma-Aldrich) before splitting or each treatment. The cells cultured
under hypoxic conditions were maintained in a chamber with 2% O2.

Chemicals and Reagents
NAC, rotenone, antimycin, 4(2′-aminoethyl) amino-1,8-dimethylimidazo(1,2-a)
quinoxaline (BMS-345541), carmustine (BCNU), temozolomide (TMZ), and 3-BrPA were
purchased from Sigma-Aldrich. 3-BrOP was synthesized by esterification of 3-bromo-232

oxopropionate (Sigma-Aldrich) with 1-propanol (Sigma-Aldrich) under acidic conditions
followed by neutralization with sodium carbonate and evaporation of the excess 1-propanol
under a vacuum (178).

RNA Isolation and RNA Microarray Analysis
GSC11 cells were cultured in stem cell medium or differentiated medium for 1, 3,
and 7 days in triplicate. Total RNA was extracted from 12 samples using the RNeasy Mini
kit (QIAGEN Inc; Valencia, CA). Sample labeling was performed with an RNA
amplification kit according to the manufacturer’s instructions (Applied Biosystems; Foster
City, CA). We used 700 ng of total RNA for labeling and hybridization on HumanHT-12 v3
expression beadchip (Illumina Inc; San Diego, CA) according to the manufacturer’s
protocols (Illumina). After the bead chips were scanned with a BeadArray Reader (Illumina),
the microarray data were normalized using the quantile normalization method in the Linear
Models for Microarray Data (LIMMA) package in the R language (http://www.rproject.org). The expression values of each gene were log2-transformed before further
analysis. Primary microarray data are available in the National Center for Biotechnology
Information Gene Expression Omnibus public database. BRB-ArrayTools were primarily
used for statistical analysis of gene expression data (182). The t test was applied to identify
the genes significantly different between two groups when compared. Cluster analysis was
performed using the software programs Cluster and Heatmap was generated by Treeview
(183).
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Real-Time PCR Analysis
The total RNA was reverse transcribed using a complementary DNA (cDNA)
synthesis kit (Fermentas Inc; Glen Burnie, MD). The quantitative polymerase chain reaction
analyses were carried out in a 25 µl reaction mixture that contained 1µl cDNA, 0.1µg
oligonucleotide

primer

pairs,

12.5

µl

SYBR

Green

Mix

(Invitrogen)

and

diethylpyrocarbonate-treated water with the following primer sets (Table 2).

Table 2. Human PCR primers for detecting levels of mRNA expression.
Gene

Forward

Reverse

SOX2

GCCTGGGCGCCGAGTGGA

GGGCGAGCCGTTCATGTAGGTCTG

Olig2

TGCGCAAGCTTTCCAAGA

CAGCGAGTTGGTGAGCATGA

CD133

CAGTCTGACCAGCGTGAAAA

GGCCATCCAAATCTGTCCTA

Notch1

GTGACTGCTCCCTCAACTTCAAT

CTGTCACAGTGGCCGTCACT

APH1B TTTCCGCGGTGGCCATGACT

GAAGTGCTGGTTCCCTGAGG

DLL1

CCTACTGCACAGAGCCGATCT

ACAGCCTGGATAGCGGATACAC

DTX3

TCCCTAAATGCCAGACTTGG

GGACAGGACGAACGACATTT

HES5

GCACCAGCCCAACTCCAAAC

TGCAGGCACCACGAGTAGCC

LFNG

GATGACTGCACCATTGGCTACA

GGCACCTGCTGCAGGTTCT

MFNG

GCGGTACCACTTGAACCTGT

ATGTCTGTTCCCTGGTCCTG
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Human Taqman probes were also used for detecting CD133, SOX2, Olig2 and 18S
(Table 3).
Table 3. Human Taqman primers for detecting levels of mRNA expression. Taqman
primers from Applied Biosystems for the indicated genes and their sequence ID are provided.
Primer

Assay I.D.

CD133

Hs01009250_m1

SOX2

Hs01053049_s1

Olig2

Hs00377820_m1

18S

Hs03928985_g1

Flow Cytometric Analysis of CD133
The cells were dissociated into single cells by using Accutase reagents (SigmaAldrich) and were stained by allophycocyanin (APC)-conjugated CD133/1 clone AC133
antibody (MACS Miltenyi Biotec, Cologne, Germany) or IgG2b-APC (MACS) according to
the manufacturer’s instructions. 10µl propidium iodide (PI) was added before flow
cytometry was performed.

Immunocytochemistry
Human neural stem cell functional identification kit (R&D Systems; Minneapolis,
MN) was used for immunocytochemistry assay. Cells were grown on chamber slides coated
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with laminin or in flasks and fixed with 10% formalin and permeablized with 0.3% Triton
X-100

or fixed

with -20°C

100% methanol.

After blocked

with

3% Goat

serum+10%BSA/PBS for 30-60 minutes, cells were incubated with the primary antibodies
diluted in 1%BSA/PBS over night and washed with PBS for 3 times. FITC conjugated goat
anti-mouse IgG or Rhodamine red conjugated goat anti-mouse IgG were diluted in
1%BSA/PBS and added onto the cells. The slides were washed with PBS for 3 times,
stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) and observed under
confocal microscope (Nikon).

Immunoblotting
Cultured cells were washed in PBS and homogenized in lysis buffer. Whole lysate
was used and 20 µg protein was applied for each sample. Cell lysates were separated by
electrophoresis on 10% or 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes. After blocking with 5% non-fat milk/PBST for
1 hour, the membranes were incubated overnight with primary antibodies at 4°C. Rabbit
anti-human SOX2 (Cell Signaling Technology Inc; Danvers, MA), rabbit anti-human Olig2
(Abcam; Cambridge, MA), mouse anti-human CD133 (MACS Miltenyi Biotec), rabbit antihuman Catalase (EMD Chemicals; Gibbstown, NJ), sheep anti-human SOD1 (EMD
Chemicals), rabbit anti-human SOD2 (Santa Cruz Biotechnology Inc; Santa Cruz, CA),
rabbit anti-human γ-GCSc (Santa Cruz), mouse anti-human phospho-IκBα (Cell Signaling;
Danvers, MA ), mouse anti-human IκBα (Cell Signaling), rabbit anti-human phosphor-p65
(Cell Signaling), rabbit anti-human p65 (Cell Signaling), rabbit anti-human phosphor-H2AX
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(EMD Millipore; Billerica, MA) rabbit anti-human H2AX (EMD Millipore) and mouse antihuman β-actin (Sigma-Aldrich) were used as primary antibodies. The primary antibody was
incubated at 4°C overnight and the secondary antibody was incubated for 1 hour at room
temperature.The primary antibodies were detected with horseradish peroxidase-conjugated
secondary antibodies. The membranes were developed using a Pierce Supersignal West Pico
Chemiluminescent Substrate (Fisher Scientific Inc; Pittsburgh, PA).

Measurement of Intracellular ROS
Cells were plated in 6 well plates in stem cell medium or FBS-containing medium
for 1, 3, or 7 days. Before performing the experiments, all samples were collected and
dissociated into single cells by accutase. We washed cells with PBS once and resuspended
them in prewarmed PBS containing freshly made solutions of 1µM CM-H2DCFDA or 5µM
MitoSOX-Red (Molecular Probes; Eugene, OR) and incubate them at 37°C for 30 and 15
minutes, respectively. After loading, we spun the cells in PBS, washed them in PBS twice
and performed the flow cytometric analysis.

Glutathione Assay
Measurement of total intracellular glutathione was performed by using a glutathione
assay kit according to the manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI,
USA). The GSC cells were cultured in serum-free for 7 days or cultured in 5% FBScontaining medium for 1, 3 or 7 days. Subsequently, the cells were washed with PBS,
harvested by centrifuging or by using a rubber policeman and were sonicated in cold MES
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buffer. A small portion of the supernatant was kept for the BCA protein assay (Pierce,
Rockfold, IL). 1% 2-vinylpyridine solution was added to the residual supernatant for
deproteinization and kept at -80°C till measurement.

Oxygen Consumption Assay
Samples were harvested and dissociated into singles cells by accutase, washed with
PBS once and suspended in fresh 37°C medium pre-equilibrated with 21% oxygen at 4~10
million cells/ml in stem cell medium. Oxygen consumption was measured in 1-ml medium
in a sealed respiration chamber equipped with a thermostat control and microstirring device
using an Oxytherm electrode unit (Hansatech Instruments Ltd; Norfolk, UK) at 37°C for 10
to 20 minutes. Oxygen consumption by these cells in the chamber was measured and
constantly monitored at 37°C using a Clark-type oxygen electrode (Hansatech Instruments).
The oxygen consumption was expressed in nanomoles of O2 consumed as a function of time
(nmol/ml/minute).

Cell Viability Assay
Cell-growth inhibition was assayed using a colorimetric assay with MTS (Promega).
Briefly, GSCs were seeded in 96-well plates and then treated with indicated compounds at
various concentrations. After 72 hours of incubation, 40 µl of the MTS solution was added
to each well and then incubated for another 4 hours. The absorbance in each well at 490 nm
was measured using a Multiskan plate reader (Thermo Scientific). Cell apoptosis and
necrosis were measured using flow cytometric analysis of cells double-stained with FITC38

annexin-V and propidium iodide. Briefly, samples were collected, dissociated, washed with
cold PBS, and suspended in the annexin-V binding buffer, and then stained with annexin-V
for 15 minutes at room temperature, washed, and stained with PI. The samples were
analyzed using a FACSCalibur flow cytometer equipped with the CellQuest Pro software
program (Becton-Dickinson).

Tumor Sphere Forming Assay
GSCs were treated with indicated compounds for 3 hours and then seeded in fresh
medium in 96-well plates at cell numbers from 10 to 1000 cells per well and incubated at
37°C under normoxia condition; neurospheres were counted under a microscope (Nikon)
after 3 weeks of incubations.

Glucose Uptake Assay
GSCs were induced by 10% FBS for 20 days and then compared with the control
GSCs. Briefly, the medium in the cell culture were replaced with the glucose-free medium
and incubated for 2 hours at 37°C, and then incubated with [3H]-2-deoxyglucose (0.4 µCi/ml)
for another hour. After washing with cold PBS, each sample was suspended in 0.5 ml of
water and transferred to a vial with 3 ml of scintillation fluid. The radioactivity of the
samples was detected using a liquid scintillation machine (Beckman Coulter).
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Lactate Production Assay
To measure the lactate production by GSCs in long-term culture, GSCs were plated
in six-well plates with the fresh medium for indicated times. Aliquots of the culture medium
were analysed by an Accutrend lactate analyzer (Roche). To measure the lactate production
in short-term culture, cells were plated in 96-well plates and treated with indicated
compounds for 3 hours. A colorimetric lactate assay kit was used according to the
manufacturer’s protocol (Eton Bioscience). Absorbance in each well at 490 nm was
measured using a Multiskan plate reader.

ATP Depletion Assay
GSCs were plated in 96-well plates and then treated with indicated compounds for 3
or 6 hours, 100 µl of mixed CellTiter-Glo luminescent reagent (Promega) was added to each
well and incubated for 10 minutes on an orbital shaker. Luminescence in each well was
measured using a Fluoroskan luminescence scanner (Thermo Scientific).

Single-Cell Gel Electrophoresis Assay (Comet Assay)
After GSCs were treated with indicated compounds for 3 hours, cell suspensions
mixed with 0.5% low-melting-point agar was placed onto a 24 × 50-mm slide precoated
with 1% normal-melting-point agar. After agar distribution and solidification, slides were
soaked

in

a

prechilled

fresh

lysing

solution

(2.5

µM

NaCl,

100

mM

ethylenediaminetetraacetic acid, 10 mM Tris-HCl, 1% Triton X-100, pH 10) for 1 hour at
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4°C. After rinsing with 0.4 M Tris buffer (pH 7.5), slides were placed in a reservoir filled
with fresh electrophoresis buffer (300 mM NaOH, 1 mM ethylenediaminetetraacetic acid,
pH >13) for 15 minutes and electrophoresed for another 15 minutes (25 V, 300 mA). Slides
were then stained with CYBR Green I (Trevigen) and photographed under a fluorescent
microscope (Nikon). The tail DNA percentage, which indicates damaged DNA, was
analyzed using the Casp software program (version 1.2.2) provided by the CASPLab Comet
Assay Project.

GAPDH Enzymatic Activity Assay
Purified GAPDH enzyme from rabbit muscle (Sigma-Aldrich) or protein extracts
prepared from GSC11 cells were used in the GAPDH assays in vitro, using GAPDH Assay
Kit (ScienCell) according to the manufacturer’s protocol. Purified GAPDH was incubated in
vitro with the indicated compounds (BCNU and 3-BrOP) for 30 minutes, then added to a
mixture of 6.67 mM 3-phosphoglyceric acid, 3.33 mM L-cysteine, 117 µM β-NADH, 1.13
mM ATP, 3.33 U/ml 3-phosphoglycerate kinase, and 100 mM triethanolamine buffer (pH
7.6), and change in NADH fluorescence was then monitored using a Fluoroskan
spectrometer every minute for up to 20 minutes. For analysis of GAPDH activity in cell
extracts, GSC11 cells were first incubated with or without 3-BrOP, BCNU, or their
combination for 30 min, and protein lysates were prepared and immediately used for
GAPDH activity assay without addition of 3-BrOP or BCNU in vitro.
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Tumorigenicity in Subcutaneous Mouse Xenografts
GSC11 cells cultured under neural sphere culture conditions (GSC medium) as
mentioned above were divided into 4 groups. One group continued to be cultured in the
GSC medium, another group was cultured in GSC medium supplemented with 5%FBS, the
third group was cultured in GSC medium in the presence of 20mM NAC and the last group
was cultured in GSC medium with 5% FBS and 20mM NAC. After 7 days, cells were
collected, treated with accutase into single cells and inoculated into the right flank of nude
mice at 2×106 cells/mouse. The mice were euthanized when the tumor diameter was greater
than 20 mm.

3-BrOP and BCNU Treatment
GSC11 cells were cultured in GSC medium and made into single cells by accutase.
The same amount of GSC11 cells were exposed to PBS, 20µM BCNU, 20µM 3-BrOP or
20µM BCNU and 20µM 3-BrOP in GSC medium and cultured at 37°C. After 6 hours, cells
were collected, washed and inoculated into SCID mice brain at 2×105 cells/mouse. The
mice were euthanized when they developed signs of neurological deficit or became
moribund.

Statistical Analysis
Data were analyzed using GraphPad Prism 5 (GraphPad Software). Data graphed
with error bars represent mean and SEM from experiments done in triplicate unless
42

otherwise noted. A two-sided Student’s t test was used to determine the significance of any
differences. Survival curves were compared between different groups by Logrank Test.
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CHAPTER 3
Mitochondrial function and ROS increase in serum-induced
GSC differentiation
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Establishment of GSC culture and induction of aberrant differentiation by serum
We used three human glioblastoma stem cell lines (GSC11, GSC23, and GBM3752)
in this study. GSC11 and GSC23 were originally derived from fresh surgical specimens of
adult glioblastoma multiforme and maintained in serum-free neural sphere culture medium
(184, 185). GBM3752 cells were derived from fresh surgical specimen of glioblastoma
multiforme, inoculated into SCID mice’s brain and passed in SCID mice as orthotopic brain
tumors (181). GBM3752 cells were prepared freshly for in vitro study in serum-free medium
during the first several passages. These cells all grew in serum free stem cell medium
(DMEM/F-12 medium) containing EGF and bFGF, and exhibited the morphology of stemlike neurospheres (Figure 6). The presence of serum (5% FBS) in culture medium caused a
significant change in cell morphology, manifested by a loss of neurosphere formation and
the appearance of differentiated cells attaching to the culture dishes (Figure 6).
About 50%-60% of GSC11 and GSC23 cultured under serum free medium were
CD133-positive cells (Figure 7A). Adding FBS into the culture medium caused a substantial
decrease of CD133 expression in a time-dependent manner (Figure 7A-B). After 3 days
cultured in serum-containing medium, the percentage of CD133+ cells dropped to 30-45% in
GSC11 cells, which was significantly decreased compared to the cells cultured in serum-free
medium. After 7 days cultured in serum-containing medium, the percentage of CD133+
GSC11 cells further dropped to around 20%. The decrease of CD133 expression was
confirmed by western blot (Figure 7C). The similar time-dependent decrease of CD133+ was
also observed in GSC23 cells (Figure 7D-E).
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Figure 6. Serum induces GSCs aberrant differentiation. Glioblastoma stem cells
(GSC11 and GBM3752) formed neurospheres in the serum-free medium
supplemented with EGF and bFGF. Exposure of the cells to serum (5% FBS) for 3
days led to a loss of neurosphere formation in both cell lines.
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Figure 7. Serum causes CD133 decrease. (A) Flow cytometric analysis of CD133
expression in GSC11 cells before and after exposure to serum for 7 days. (B)
Quantitation of the percentage of CD133+ cells before and after GSC11 cells
exposed to serum for 1, 3, and 7 days. *, P<0.05. (C) Western blot analysis of
CD133 expression in GSC11 cells before and after exposure to serum for 1, 3, and 7
days as indicated. (D) Flow cytometric analysis of CD133 expression in GSC23
cells before and after exposure to serum for 7 days. (E) Quantitation of the
percentage of CD133+ cells before and after GSC23 cells were exposed to serum for
1, 3, and 7 days. *, P<0.05.
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Quantitative RT-PCR and western blot analyses of GSC11 cells revealed a
significant decrease in mRNA expression of SOX2 and Olig2, two transcription factors that
are important for neural stem cells and neural progenitor cells, in serum-induced cells
(Figure 8A). The mRNA expression of Notch1, a molecule important for promoting neural
stem cell function(186), was also significantly down regulated in serum-induced cells
(Figure 8A). The downregulation of SOX2 and Olig2 was also detected on protein levels by
western blot (Figure 8B). In contrast, the expression of a differentiation marker ANXA1 was
significantly increased after exposure of GSC11 cells to serum (Figure 8B). Similar results
were obtained from GSC23 cells (Figure 8C-D).
High expression levels of a neural stem cell marker Nestin was detected in GSC
spheres by immunocytochemistry (Figure 9). The exposure to FBS did not cause obvious
change in Nestin expression. Glial fibrillary acidic protein (GFAP), a marker which is often
detected in astrocytes, was also detected in GSC spheres by immunocytochemistry (Figure
10). Serum exposure did not cause substantial change of GFAP expression. Low level
expression of a neuron marker β-III tubulin and an oligodendrocyte marker O4 was detected
in GSC cells and serum induction caused an upregulation of both proteins (Figure 11).
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Figure 8. Serum causes decreases of SOX2, Olig2 and Notch1 and an increase of
ANXA1. (A) Expression of SOX2, Olig2, and Notch1 mRNA in GSC11 cells before
and after exposure to serum for 3 days. Expression of mRNA was measured by
quantitative real-time PCR. **, P<0.001 *, P<0.05. (B) Effect of serum exposure on
protein expression of stem cell markers SOX2 and Olig2 and differentiation marker
ANXA1. GSC11 cells were exposed to 5% FBS for 1, 3, and 7 days (D1, D3, D7).
SOX2, Olig2, ANXA1 were detected by western blot analysis. (C) Expression of
SOX2, Olig2, and Notch1 mRNA in GSC23 cells before and after exposure to serum
for 3 days. Expression of mRNA was measured by quantitative real-time PCR. **,
P<0.001 *, P<0.05. (D) Effect of serum exposure on protein expression of stem cell
markers SOX2 and Olig2 and differentiation marker ANXA1. GSC23 cells were
exposed to 5% FBS for 1, 3, and 7 days (D1, D3, D7) as indicated, and cellular
proteins were analyzed for expression of SOX2, Olig2 and ANXA1 by western
blotting.
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Figure 9. GSCs express Nestin. (A) Expression of Nestin (green) in GSC11
neurospheres was detected by immunocytochemistry staining. Counterstaining of
the nuclei with DAPI is depicted (blue). (B) Immunocytochemistry staining of
Nestin (green) and DAPI (blue) in GSC11 cells cultured in GSC medium or
exposed to 5% FBS for 7 days.
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Figure 10. GSCs express GFAP. (A) Expression of GFAP (green) in GSC11
neurospheres by Immunocytochemistry staining. Counterstaining of the nuclei with
DAPI is depicted (blue). (B) Immunocytochemistry staining of GFAP (green) and
DAPI (blue) in GSC11 cells cultured in GSC medium or exposed to 5% FBS for 7
days.
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Figure 11. Expression of β-III tubulin and O4 increases in serum-induced GSC11
cells. (A) Immunocytochemistry staining of β-III tubulin (red) and DAPI (blue) in
GSC11 cells cultured in GSC medium or exposed to 5% FBS for 7 days. (B)
Immunocytochemistry staining of O4 (red) and DAPI (blue) in GSC11 cells cultured
in GSC medium or exposed to 5% FBS for 7 days.
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FBS causes gene expression change in aberrant differentiated cells
To investigate the molecular events and potential alterations of signaling pathways in
response to serum-induced differentiation in the glioblastoma stem cells, we treated GSC11
cells with 5% FBS for 1, 3, and 7 days in triplicate cultures, and isolated RNA from each
sample for determination of gene expression profiles. As shown in Figure 12A, clustering
analysis of the gene expression data from microarray analysis revealed that the serumtreated GSC11 cells exhibited gene expression profiles distinct from that of the GSC11 cells
cultured in serum-free medium. There was a further shift of gene expression profiles as the
time of serum exposure prolonged. The fact that three separate samples of the same time
point (biological triplicates) displayed similar gene expression patterns and clustered in the
same group reflects the high reproducibility of this experimental system. Using the
Ingenuity Pathway Analysis software, we compared the gene expression between GSCs and
aberrant differentiated cells and we found that the Nrf2 mediated oxidative stress response
pathway was the most significant alteration (p = 0.00045) in cells cultured under serum
condition for 1 day. On the first day of initiating differentiation, the molecules related to
Nrf2 mediated oxidative stress response pathway were significantly altered (Figure 12B).
Table 4 shows the genes involved in oxidative stress response identified by this analysis in
GSC11 cells. Among the genes identified, SOD2, catalase, NQO1, peroxiredoxin 1,
thioredoxin reductase 1, and glutamate-cysteine ligase are involved in ROS scavenging.
These results suggest that serum-induced differentiation of GSCs was likely associated with
oxidative stress.
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Figure 12. The gene expression changes in aberrant differentiated cells. (A)
Overall gene expression pattern of GSC11 cells. GSC11 cells maintained in serumfree stem cell medium were exposed to 5% FBS for 1, 3, and 7 days (each time
point had triplicate culture flasks A-C). After variance filtering, a total of 7613
probes were used for unsupervised hierarchical clustering with the similarity metric
of uncentered correlation. The red and green colors represent high and low
expression, respectively, as indicated in the log2-transformed scale bar. (B)
Expression pattern of genes associated with the Nrf2-mediated oxidative stress
response pathway. Genes with expression showing significant difference between
control and 1 day in serum-free condition in GSC11 cells were selected by twosample t-test (P < 0.001). Expression values of each gene in 1, 3 and 7 days were
normalized by its mean value of controls, and visualized.
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Table 4. The significantly changed genes in the Nrf2-mediated oxidative stress response
pathway.
Gene

p value(Day1 vs Control)

Fold change (Day1 vs Control)

GSTM1

0.0008

-3.18

GSTM2

4.3E-05

-3.44

CAT

0.00078

-1.83

GSTT1

0.00028

-2.49

GSTM1

0.00043

-2.06

JUND

0.00068

-1.65

GSTM2

0.00057

-2.82

PIK3R2

0.0002

-1.89

PRKCZ

0.00011

-1.76

MAF

0.0008

-2.02

MAP3K1

0.00091

-1.78

PIK3R1

0.00029

-2.63

SCARB1

6.1E-05

-2.39

JUNB

6.7E-05

2.53

MAFG

0.00044

1.76

GCLM

6.8E-05

2.26

TXNRD1

2.7E-05

1.60

HMOX1

0.00017

3.06

JUN

7.5E-05

2.37

NQO1

0.00042

2.22

SOD2

0.00051

1.78
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MAP2K3

0.00061

1.71

PRDX1

0.00029

1.30

NSMAF

0.00063

1.41

ACTG1

0.00057

1.17
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Serum induces increase of mitochondrial superoxide
The observations that exposure of GSCs to serum caused a consistent oxidative
stress response prompted us to test possible changes in cellular redox status. Since
mitochondria are the major sites of ROS production, we used MitoSox Red to detect
mitochondrial superoxide (O2-) and 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein
diacetate acetyl ester (DCF-DA) to measure total cellular H2O2 and other ROS. We found
that serum induced a substantial increase of mitochondrial O2- in a time-dependent manner,
with an increase of median value from 46 units in control cells (without serum) to 67, 188,
and 268 units on day 1, day 3, and day 7 after serum exposure, respectively (Figure 13A).
Total cellular H2O2 and other ROS as measured by DCF-DA also showed an increase, from
84 units in the control to 112, 126, and 159 units on day 1, day 3, and day 7, respectively
(Figure 13B). Similar results were also observed in GSC23 (Figure 13C-D) and GBM3752
(Figure 13E-F), suggesting that the induction of mitochondrial O2- generation might be an
important early event in serum-induced differentiation of GSCs.
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Figure 13. Effect of serum on mitochondrial superoxide and cellular ROS.
Mitochondrial superoxide was measured by flow cytometric analysis after cells
were stained with MitoSOX-Red. Cellular ROS were detected using CM-H2DCFDA staining followed by flow cytometric analysis. The numbers in
parentheses indicate the median fluorescent intensity. (A) Increase of mitochondrial
superoxide in GSC11 cells after exposure to 5% FBS for 1, 3, and 7 days (D1, D3,
D7). (B) Analysis of total cellular H2O2 and other ROS in GSC11 cells before and
after exposure to serum. (C) Increase of mitochondrial superoxide in GSC23 cells
after exposure to 5% FBS for 1, 3, and 7 days. (D) Analysis of total cellular H2O2
and other ROS in GSC23 cells before and after exposure to serum for 3 and 7 days.
(E) Increase of mitochondrial superoxide in GBM3752 cells after exposure to 5%
FBS for 3 days (D3). (F) Analysis of total cellular H2O2 and other ROS in
GBM3752 cells before and after exposure to serum for 3 days.
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We then tested if the alterations in mitochondrial O2- and cellular ROS might cause
stress response and upregulation of antioxidant enzymes. As shown in Figure 14, there was a
time-dependent increase in expression of SOD2, a mitochondrial superoxide dismutase that
converts O2- to H2O2. Interestingly, the cytosolic superoxide dismutase (SOD1) did not
exhibit any significant change after serum exposure (Figure 14A). The expression of
catalase, an enzyme that converts cellular H2O2 to water and oxygen, increased after serum
incubation (Figure 14A). Similar results were obtained from GSC23 (Figure 14B). These
data together suggest that the increased expression of SOD2 might be a specific stress
response to elevated mitochondrial O2- generation induced by serum. SOD2 converted O2- to
H2O2, which was then able to pass the mitochondrial membranes and further converted to O2
and H2O by catalase, resulting in a moderate overall increase of total cellular ROS detected
by DCF-DA.

Figure 14. Effect of serum on expression of SOD1, SOD2 and catalase. (A)
Western blot analysis of SOD1, SOD2, and catalase in GSC11 cells before and after
exposure to serum for 1, 3 and 7 days (D1, D3, D7). (B) Western blot analysis of
SOD1, SOD2, and catalase in GSC23 cells before and after exposure to serum for 1,
3 and 7 days (D1, D3, D7).
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Total glutathione (GSH), the major endogenous antioxidant, became deficient in a
time-dependent manner in the GSC11 aberrant differentiated cells (Figure 15A).

For

GSC23 cells induced by serum, total GSH increased on day 1 and decreased subsequently
on day 3 and day 7 (Figure 15B). A rate limiting enzyme in GSH biosynthesis, γglutamylcysteine synthetase heavy subunit (γ-GCSc), increased in aberrant differentiated
GSC11 on day 7 (Figure 15C). These results suggested that serum induction caused
oxidative stress that led to an upregulation of GSH synthesis enzyme. But this stress
response failed to provide sufficient GSH for the cells to scavenge the oxidative stress.
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Figure 15. Serum induction causes glutathione depletion. (A)Total GSH/protein
ratio in GSC11 cells before and after exposure to serum for 1, 3 and 7 days. (B) Total
GSH/protein ratio in GSC23 cells before and after exposure to serum for 1, 3 and 7
days. (C) WB blot detection of γ-GCSc expression in GSC11 cells before and after
exposure to serum for 1, 3 and 7 days.
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Activation of mitochondrial respiration by serum in glioblastoma stem cells
Since mitochondrial superoxide is mainly generated during respiration due to a
release of electrons from complexes I and III of the electron transport chain, we speculated
that the increased mitochondrial O2- might be a result of active mitochondrial respiration
induced by serum, and not a consequence of a slower superoxide elimination since SOD2
expression was increased. To test this possibility, we measured oxygen consumption by
GSCs as an indicator of mitochondrial respiration. As shown in Figure 16A-B, exposure of
GSC11 cells to serum led to a time-dependent significant increase of oxygen consumption,
with approximately 100% increase by day 3. The increase in mitochondrial respiration was
also consistently observed in GSC23 (Figure 16C) and GBM3752 cells (Figure 16D).
Since the oxygen consumption increase in aberrant differentiated cells might be due
to mitochondria quantity increase or mitochondrial function increase, we further measured
the mitochondria quantity by using a fluorescent dye, MitoTracker Green. Flow cytometric
analysis showed that serum did not cause any significant change in mitochondrial mass
(Figure 17A), suggesting that the increased respiration was mainly a functional activation of
mitochondria instead of an increase of mitochondria biogenesis. Similarly, no significant
changes in mitochondrial mass were observed in GSC23 (Figure 17B) and GBM3752 cells
(Figure 17C).
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Figure 16. Increase of mitochondrial respiration in aberrant differentiated cells.
(A) Comparison of oxygen consumption in GSC11 cells before and after exposure to
serum for 1, 3 and 7 days. Oxygen consumption was measured using an Oxytherm
system as described in Methods. (B) Quantitative analysis of oxygen consumption in
GSC11 cells exposed to serum for 1, 3, and 7 days. *, P<0.01. (C) Quantitative
analysis of oxygen consumption in GSC23 cells exposed to serum for 3 days. *,
P<0.01. (D) Comparison of oxygen consumption in GBM3752 cells before and after
exposure to serum for 3 days.
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Figure 17. Serum does not induce mitochondria biogenesis. Mitochondrial mass
was measured by MitoTracker-Green. No change in mitochondrial mass was found in
GSC11 (A), GSC23 (B) and GBM3752 (C) cells after exposed to serum for 1 day
(D1), 3 days (D3), or 7days (D7). The numbers in parentheses indicate the median
fluorescent values.
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CHAPTER 4
ROS mediate GSC differentiation in response to serum
induction
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Oxidative respiration inhibitor CCCP does not inhibit serum-induced aberrant
differentiation.
The effect of carbonyl cyanide m-chloro phenyl hydrazone (CCCP), a mitochondrial
uncoupling agent that causes an uncoupling of the proton gradient and reduces ATP
synthesis, on aberrant differentiation was tested. Different dosages of CCCP were used to
treat the GSC11 cells, which showed that 5µM of CCCP didn’t cause much cell death (data
not shown). Therefore, 2µM and 5µM of CCCP were used to test its effects on inhibiting the
stem cell related gene expression change. 5 µM of CCCP prevented the decrease of CD133
induced by serum in GSC11 cells (Figure 18A), but no inhibition of SOX2 and Olig2
mRNA decreases was found by real-time PCR (Figure 18A). CCCP either didn’t inhibit the
decrease of SOX2 and increase of ANXA1 caused by serum on protein levels (Figure 18B).
We measured the mitochondrial superoxide change in the GSC11 cells treated by CCCP.
The results showed that CCCP did not inhibit the mitochondrial superoxide increase in
aberrant differentiated cells (Figure 19).
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Figure 18. Effects of mitochondrial uncoupler CCCP on the expression of SOX2,
Olig2, CD133 and ANXA1. (A) mRNA expression of SOX2, Olig2 and CD133 in
GSC11 cells, as measured by quantitative RT-PCR. GSC11 were exposed to serum
(5% FBS) for 3 days in the presence and absence of 2µM or 5µM CCCP. *, p<0.05.
(B) mRNA expression of SOX2, Olig2 and CD133 in GSC23 cells, as measured by
quantitative RT-PCR. GSC23 were exposed to serum (5% FBS) for 3 days in the
presence and absence of 2µM or 5µM CCCP. *, p<0.05. (C) Protein levels of SOX2,
Olig2 and CD133 in GSC11 and GSC23 cells, as measured by western blot. GSC11
and GSC23 cells were cultured with or without presence of serum (5% FBS) for 3
days in the presence and absence of 2µM or 5µM CCCP.
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Figure 19. CCCP can’t inhibit mitochondrial superoxide increase.
Mitochondrial superoxide was measured by flow cytometric analysis after cells
were stained with MitoSOX-Red. GSC11 cells were cultured in GSC medium
or FBS-containing medium with or without the presence of 2µM or 5µM of
CCCP for 1 day.
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Compounds increasing mitochondrial superoxide cause CD133 decrease
In order to test whether the activation of mitochondrial function would affect serum
induced aberrant differentiation, several mitochondrial electron transport chain inhibitors
were used to disrupt mitochondrial function. Mitochondria ETC complex I inhibitor
rotenone and complex III inhibitor antimycin were added with serum to the GSCs. Both
ETC inhibitors caused an increase of mitochondrial superoxide (Figure 20). Neither of them
prevented the GSCs from attaching to the flasks and showing differentiated morphology
(Figure 21A). Adding rotenone or antimycin even caused further decreases of CD133 on
both mRNA and protein levels (Figure 21B-C).

Figure 20. Mitochondrial electron transport chain inhibitors antimycin and
rotenone cause increase of mitochondrial superoxide. Mitochondrial superoxide
was measured by flow cytometric analysis after cells were stained with MitoSOXRed. GSC23 cells were cultured in GSC medium or FBS-containing medium with
2µM antimycin or 1µM rotenone.
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Figure 21. Antimycin and rotenone cause further decrease of CD133 in seruminduced cells. (A) GSC11 cells were cultured in GSC medium or FBS-containing
medium with 2µM antimycin or 1µM rotenone. (B) mRNA levels of CD133 were
measured by real-time PCR after GSC23 cells were cultured in GSC medium or FBScontaining medium with 2µM antimycin or 1µM rotenone. (C) GSC23 cells were
cultured in GSC medium or FBS-containing medium with or without the presence of
2µM antimycin or 1µM rotenone. Protein levels of CD133 were measured by western
blot.
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H2O2 causes the stem cell markers gene expression decrease
Exposure of GSCs to serum caused an increase in mitochondrial respiration and O2generation. However, neither the mitochondria ETC inhibitors (rotenone and antimycin) nor
the oxidative phosphorylation inhibitor (CCCP) prevented the stem cell markers decrease or
differentiation marker increase. Rotenone and antimycin caused further increase of
mitochondrial superoxide and induced further CD133 decreases. Therefore, it seems
mitochondrial ROS instead of the activation of mitochondria itself plays an important role in
aberrant differentiation. I further tested the potential role of ROS increase in serum-induced
differentiation by using hydrogen peroxide. H2O2 caused a similar increase of mitochondrial
ROS as serum did in GSC11 and GSC23 cells (Figure 22A-B). The short-term treatment of
H2O2 led to significant decreases of SOX2, Olig2 and CD133 mRNA expression in GSC11
cells (Figure 22C). Similarly, the short-term treatment of H2O2 caused significant decreases
of SOX2 and CD133 mRNA expression in GSC23 cells (Figure 22D).
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Figure 22. Hydrogen peroxide causes mitochondrial superoxide increase and
decreases of Olig2, SOX2 and CD133. (A) Mitochondrial superoxide was measured
by flow cytometric analysis before or after GSC11 cells were treated with 200µM or
1mM of H2O2 for 1 hour. (B) Mitochondrial superoxide was measured by flow
cytometric analysis before or after GSC23 cells were treated with 500µM or 1mM of
H2O2 for 1 hour. (C) mRNA expression of SOX2, Olig2 and CD133 in GSC11 cells, as
measured by quantitative RT-PCR. GSC11 were treated with 200µM or 1mM H2O2 for
6 times with 1 hour intervals. *, p<0.05. (D) mRNA expression of SOX2, Olig2 and
CD133 in GSC23 cells, as measured by quantitative RT-PCR. GSC23 were treated
with 500µM or for 6 times with 1 hour intervals. *, p<0.05.
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Antioxidant NAC prevents the serum-induced differentiation
N-Acetyl-Cysteine (NAC), a precursor for glutathione synthesis with potent
antioxidant property capable of reducing various types of ROS stress, was used to prevent
the increase of mitochondrial O2- in serum-treated GSCs.

As shown in Figure 23A,

incubation of GSC11 cells with serum for 7 days caused a significant increase of
mitochondrial O2-, and 20µM of NAC effectively suppressed such ROS increase. Similar
results were obtained from GSC23 cells (Figure 23B).

Figure 23. NAC suppresses serum-induced mitochondrial superoxide
increase. Mitochondrial superoxide was detected by flow cytometry after cells
were stained with MitoSox-Red. (A) GSC11 cells were cultured in serumcontaining medium with or without the presence of 20mM NAC for 7 days. (B)
GSC23 cells were cultured in serum-containing medium with or without the
presence of 20mM NAC for 7 days.
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Importantly, NAC was able to prevent serum-induced differentiation and keep the
GSC11 cells in stem-like neurospheres (Figure 24A), and to preserve the expression of
CD133 in GSC11 cells (Figure 24B), suggesting that the increase in mitochondrial
superoxide might play an important role in mediating serum-induced GSC differentiation.

Figure 24. NAC prevents serum-induced aberrant differentiation. (A)
Comparison of neurosphere formation in GSC11 cells cultured in serum-containing
medium in the presence and absence of 20 mM NAC for 7 days. (B) NAC
suppressed serum-induced loss of CD133 expression. GSC23 cells were exposed to
serum for 1, 3, or 7 days in the presence or absence of 20 mM NAC as indicated,
and CD133-possitive cells were measured by flow cytometric analysis.*, P<0.05.
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Since there was a significant decrease in expression of SOX2, Olig2, and Notch1
during serum-induced differentiation, we tested if NAC could suppress serum-induced
differentiation by preventing the down-regulation of these molecules important for stem cell
maintenance. As shown in Figure 25A, quantitative RT-PCR revealed that addition of NAC
to the serum-treated GSC11 cells largely prevented the decrease of SOX2 and Olig2
expression, suggesting that the expression of these two molecules might be redox-sensitive.
Similar results were also observed in another glioblastoma stem line GSC23 (Figure 25B).
Furthermore, gene expression analysis of molecules involved in the Notch pathway revealed
that serum caused a significant decrease in the expression of Notch1, MFNG, LFNG, HES5,
DTX3, and DLL1 in GSC11 cells (Figure 25C). The presence of antioxidant NAC largely
prevented the down regulation of the Notch-related genes (Figure 25C), suggesting that
cellular redox status might play a major role in Notch signaling.
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Figure 25. Effect of antioxidant NAC on the expression of SOX2, Olig2 and
Notch pathway. Antioxidant NAC suppressed serum-induced down regulation of
SOX2 and Olig2 mRNA expression in GSCs, as measured by quantitative real-time
PCR. GSC11 (A) and GSC23 (B) were exposed to serum (5% FBS) for 3 days in the
presence and absence of 20 mM NAC. The expression of SOX2 and Olig2
messenger RNA in each sample was measured by quantitative RT-PCR. (C)
Antioxidant NAC suppressed serum-induced down regulation of the notch pathway.
GSC11 cells were incubated with serum (5%FBS) for 3 days in the presence or
absence of 20 mM NAC. RNA was isolated from each sample and the expression of
molecules involved in notch signaling was measured by quantitative real-time PCR.
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Serum induction activates NFĸB pathway
ROS seems to play an important role in mediating serum-induced differentiation. In
order to clarify the possible mechanism of how mitochondrial ROS change causes the GSC
differentiation, we analyzed the data of microarray and searched for significantly altered
gene expressions in aberrant differentiated cells. A ROS regulating signaling, NFĸB
pathway seems to be a possible candidate. Its downstream targets CD44, IL8, IL11, Cyclin
D1, TFP12 and PLAUR were significantly up-regulated in the aberrant differentiated cells
(Table 5). We assayed the NFĸB pathway by western blot and found phosphorylated IĸBα
and phosphorylated p65 were increased in serum-induced aberrant differentiated cells on
day three in both GSC11 and GSC23, indicating the activation of NFĸB pathway after serum
induction (Figure 26).

85

Table 5. NFĸB pathway downstream targets expression in the microarray analysis. The
mRNA expression signal of GSC11 cells cultured in serum-free medium and 5%FBScontaining medium for 1, 3 and 7 days. P value was calculated by t-test based on the mRNA
expression values. CD44-4, CD44 transcript variant 4; CD44-5, CD44 transcript variant 5;
IL-8, interleukin 8; IL-11, interleukin 11; PLAUR, plasminogen activator urokinase receptor;
TFP12, tissue factor pathway inhibitor 2.
Average Value of Triplicate

p Value

Cont

D1

D3

D7

Cont vs D1 Cont vs D3 Cont vs D7

CD44 -4

6.39

11.97

10.72

12.79

9.55E-08

6.16E-07

7.61E-08

CD44-5

5.66

7.90

7.72

10.02

0.000149

6.61E-05

8.96E-08

IL-11

5.75

7.77

7.10

8.16

8.80E-05

0.000715

3.62E-05

11.52

12.79

12.34

12.21

1.07E-06

1.51E-06

0.000248

TFPI2

6.58

8.7

8.53

8.67

7.74E-05

1.11E-06

0.000336

IL-8

5.61

6.29

5.68

7.23

8.66E-05

0.090

9.85E-05

PLAUR

6.04

6.04

6.66

7.29

0.99

0.00037

0.000118

Cyclin
D1
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Figure 26. NFĸB pathway activation by serum-induction. Protein samples were
obtained from GSC11 and GSC23 cells cultured in serum-free or serum-containing
medium in the presence or absence of 20mM NAC for 3 days. The protein expression
of phospho-IKBα, IKBα, phosphor-p65, p65 and β-actin was assayed by western blot.
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Inhibition of NFĸB pathway prevents CD133 decrease and ANXA1 increase.
An IKK inhibitor, BMS-345541 was used to inhibit the activation of NFĸB signaling
in GSC11 cells. The western blot results showed the inhibition of NFĸB pathway in seruminduced cells in a dose-dependent manner (Figure 27). 10 µM and 20 µM of BMS-345541
prevented the decrease of CD133 and inhibited the ANXA1 increase (Figure 27).

Figure 27. IKK inhibitor BMS-345541 prevents CD133 decrease and ANXA1
increase. GSC11 cells were cultured in serum-free or serum-containing medium
with different dose of BMS345541 or 20mM of NAC. Cells were collected after 3
days and the expression of phospho-IKBα, phosphor-p65, CD133, ANXA1 and βactin was assayed by western blot.
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Serum induction promotes tumorigenesis and malignancy in vivo
In order to test the effect of serum induction on tumor formation, we cultured the
GSC11 cells under different conditions for 7 days and inoculated the same number of cells
subcutaneously into the right flank of nude mice. Interestingly, the mice inoculated with
serum-induced cells all formed tumors (Figure 28A). However, only 2 out of 7 mice treated
with cells cultured in serum-free medium (the control group) formed tumors. There were 4
mice in the NAC group and 5 mice in the serum plus NAC group formed tumors. The
overall survival of the control group was significantly higher than the serum induction group,
with a p value 0.0019 (Figure 28B). No significant difference of overall survival was found
between the control group and NAC or serum plus NAC group.
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Figure 28. Serum induction increases tumorigenicity and malignancy in GSCs.
GSC11 cells were cultured under serum-free medium or serum-containing medium
in the presence of absence of 20mM NAC for 7 days. 2X106 cells were inoculated
subcutaneously into the right flank of each nude mouse. (A) Number of mice with
visible tumors in each group. (B) Survival curves for the mice in each group. The
mice were euthanized when the tumor diameter was greater than 20 mm.
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CHAPTER 5
Targeting metabolism with 3-BrOP and BCNU in GSCs
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GSCs exhibit high glycolytic activity and resistance to TMZ and BCNU but sensitivity
to glycolytic inhibition.
GSC11 and GSC23 were cultured in the serum-free stem cell culture medium
supplemented with EGF and bFGF. Under these culture conditions, the GSCs exhibited
relatively low mitochondrial respiration as evidenced by a low oxygen consumption rate
(Figure 29A). When the cells were induced to undergo differentiation by exposure to serum,
mitochondrial respiration was substantially activated leading to approximately 90% increase
in oxygen consumption after 20 days (Figure 29A), accompanied by a decrease in lactate
production (Figure 29C) and a significant decrease in glycolytic index (Figure 29D). This
data suggests the GSCs maintained in their stem stage had a low mitochondrial respiration
and high glycolytic activity, and serum induction activated mitochondrial oxidative
phsophorylation and reduced the need of glycolysis for energy production.
When GSC11 and GSC23 cells were treated with TMZ and BCNU for 72 hours, two
drugs commonly used in the treatment of glioblastoma, the cells showed resistance to these
conventional chemotherapeutic drugs. The MTS assay demonstrated that GSCs were more
resistant to TMZ and BCNU under hypoxic conditions than under normoxic conditions
(Figure 30). In contrast, GSCs were also sensitive to 3-BrOP under hypoxic conditions, with
the similar or lower 50% inhibitory concentrations than those under normoxic conditions.
These data are consistent with the observation that GSCs had low mitochondrial function
and thus were more dependent on glycolysis, which was inhibited by 3-BrOP, a derivative
of the alkylating agent 3-bromopyruvate known to inhibit two major glycolytic enzymes
hexokinase II and GAPDH (74, 86, 187, 188).
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Figure 29. Serum induction causes decrease of glycolysis. (A) Comparison of
oxygen consumption in GSC11 cells before and after exposure to serum for 20 days.
Oxygen consumption was measured using an Oxytherm system as described in
Methods. *, P<0.05. (B) Comparison of glucose uptake in GSC11 cells before and
after exposure to serum for 20 days. (C) Lactate generation rates in GSC11 cultured in
GSC medium and in serum-containing medium for 20 days. *, P<0.05; **, P<0.01. (D)
Comparison of glycolytic index in GSC11 cells and serum-induced differentiated cells.
**, P<0.01. Glycolytic index was calculated according to the formula (L × G)/O, in
which L is the cellular lactate production, G is the glucose uptake, and O is the oxygen
consumption rate.
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Figure 30. GSCs are resistant to chemotherapeutic agents but sensitive to
glycolytic inhibitor 3-BrOP. Sensitivity of GSCs to TMZ, BCNU, and 3-BrOP
under hypoxic and normoxic conditions. GSC11 or GSC23 cells were incubated
with the indicated concentrations of drugs for 72 h, and cell viability was measured
by MTS assay.
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Combination of 3-BrOP and BCNU shows synergistic effect in killing GSCs, especially
under hypoxic conditions
We then tested if a combination of 3-BrOP with BCNU or TMZ can lead to more
effective killing of GSCs, based on the postulation that 3-BrOP would deplete the cellular
ATP by inhibiting glycolysis and thus impair the ability of cells to repair DNA damage
induced by BCNU or TMZ. The results showed that 3-BrOP substantially potentiates the
killing effect of BCNU but not TMZ, especially under hypoxic conditions (Figure 31A-C).
Treatment with the combination of 10 µM 3-BrOP and 50 µM BCNU inhibited cell growth
by 50% in GSC11 cells (Figure 31A) and GSC23 cells (Figure 31B), whereas treatment with
either drug alone only slightly inhibited cell growth. We further confirmed the synergistic
killing effect of the 3-BrOP and BCNU combination using annexin-V/PI staining. Most
GSC11 cells were killed after 24 hours of treatment with 200 µM BCNU in combination
with 15 µM 3-BrOP, whereas we did not observe significant cell death with treatment with
either drug alone (Figure 31C). Similar results were also observed in GSC23 cells (Figure
33A). The combination index (CI), which was calculated according to various
concentrations of 3-BrOP and BCNU treatments (Table 6), was between 0.701~0.979,
suggesting a synergistic effect (CI<1) of BCNU and 3-BrOP. The cell-death pattern was
primarily necrosis, which suggests that the ATP-dependent apoptosis process was hampered
due to ATP depletion induced by 3-BrOP. The synergistic killing effects of BCNU and 3BrOP were more dramatic in hypoxia than in normoxia, as GSCs were more dependent on
glycolysis for ATP generation under hypoxia. This finding suggests that 3-BrOP could be an
effective therapeutic agent to target GSCs in hypoxic tissue environments.
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Figure 31. Effective killing of glioblastoma stem cells by combination of 3-BrOP
and BCNU. (A) Inhibition of GSC11 cells by BCNU (left panel), TMZ (right panel),
or their combination with 3-BrOP (72 h MTS assay under hypoxic conditions). (B)
Inhibition of GSC23 cells by BCNU (left panel), TMZ (right panel), or their
combination with 3-BrOP (72 h MTS assay under hypoxic conditions). (C) Induction
of cell death in GSC11 cells treated with BCNU, 3-BrOP, or their combination. Cell
were incubated with the indicated concentrations of compounds for 24 h under
normoxic and hypoxic conditions, and cell viability was measured using annexin-V/PI
double staining followed by flow cytometric analysis.
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Table 6. 3-BrOP and BCNU have synergistic effect in killing GSCs. CI was calculated
using Calcusyn software, according to the results of flow cytometric analysis in GSC11 cells
treated with BCNU, 3-BrOP alone or in combination for 24 hours in hypoxic conditions.
Combination Index (CI) of BCNU and 3-BrOP
BCNU(µM)

3-BrOP(µM)

CI

100

10

0.979

100

15

0.780

100

20

0.883

200

10

0.701

200

15

0.710

200

20

0.789
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In vitro clonogenicity is considered as an indicator of the tumor-initiating capability
of cancer cells in vivo. To assess the drug effect on clonogenicity of GSCs, we treated them
with BCNU and 3-BrOP alone or in combination for 3 hours and then evaluated their
clonogenicity using a neurosphere-forming assay. The neurosphere-formation ability of
GSCs decreased slightly when treated with 50µM BCNU or 15µM 3-BrOP alone. However,
combination of both compounds almost completely abolished the ability of GSCs to form
neurospheres (Figure 32A). The quantitation of the spheres is shown in Figure 32B. These
results indicate that GSCs underwent irreversible loss of ability to form spheres despite a
short-term combination treatment (BCNU and 3-BrOP) followed by a period of drug-free
incubation to allow for potential recovery.
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Figure 32. Effect of BCNU, 3-BrOP, or their combination on neurosphere
formation in GSCs. Pictures and quantitation of GSC11 neurospheres after incubated
with the indicated concentration of drugs for 3 hours, and then cultured in drug-free
stem cell medium for 3 weeks.
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3-BrOP in combination with BCNU preferentially kills tumor cells with relatively low
toxic effect on normal human astrocytes
Since 3-BrOP inhibit the glycolytic pathway, and cancer cells, especially GSCs, are
more dependent on this metabolic pathway to generate ATP, we hypothesized that inhibition
of glycolysis by 3-BrOP would preferentially deplete ATP in GSCs and other cancer cells,
but the non-malignant cells such as normal human astrocytes (NHAs) would be less
sensitive to such inhibition. Indeed, as shown in Figure 33, a combination of sub-toxic
concentrations of 3-BrOP and BCNU synergistically killed GSC23 cells (Figure 33A), the
serum-induced GSC11 cells (Figure 33B), and the human glioma cell line U87 cells which
were maintained in serum-containing conditions (Figure 33C). However, this drug
combination caused only minimum cytotoxicity in the immortalized NHAs (Figure 33D).
These observations suggest that normal human cells are fundamentally different from
malignant cells in their energy metabolism and sensitivity to glycolytic inhibitor, and thus
provide a therapeutic window for selectivity.
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Figure 33. Preferential killing of glioblastoma cells by 3-BrOP and BCNU. The
cytotoxic effect of 3-BrOP, BCNU, or their combination was compared in (A)
GSC23 cells, (B) serum-induced GSC11 cells, (C) U87 glioma cells, and (D) the
normal human astrocytes (NHA). Cells were incubated with the indicated drugs for
24 h under hypoxia, and cell viability was measured by annexin-V/PI double
staining followed by flow cytometric analysis.
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Severe depletion of cellular ATP by 3-BrOP and BCNU in GSCs prior to cell death
Based on the observations that GSCs were highly dependent on glycolysis for ATP
generation, we hypothesized that inhibition of glycolysis by 3-BrOP would severely deplete
ATP in GSCs. We first tested the effect of 3-BrOP or its combination with BCNU on
glycolysis in GSCs, using lactate production as an indicator of glycolytic activity. As shown
in Figure 34A, a 3-hour incubation of GSC11 cells with 100-200 µM BCNU or 15-20µM 3BrOP alone caused only slight inhibition of lactate production, and the combination of these
two compounds showed significant inhibition (Figure 34A), leading to a substantial decrease
of cellular ATP by more than 50% (Figure 34B). A prolonged incubation with both
compounds for 6 hours in hypoxia led to massive depletion of ATP (Figure 34C). It is worth
noting that incubation with 200 µM BCNU or 15 µM caused a slight reduction of ATP by
10% and 30%, respectively, while the combination of these two compounds led to more than
90% ATP depletion (Figure 34C). Similar effect of 3-BrOP and BCNU in causing ATP
depletion was also observed in GSC23 (Figure 34D). Interestingly, incubation of GSC cells
with TMZ did not cause any significant change in ATP, and this compound did not enhance
the ability of 3-BrOP to induce ATP depletion (Figure 35). This might explain why
treatment of GSCs with 3-BrOP plus TMZ did not show any enhancement of cytotoxicity.
Flow cytometric analysis of cell viability showed that GSC cells treated with 3-BrOP plus
BCNU remained largely viable at both the 3-hour and 6-hour time points (Figure 34E),
suggesting that the observed ATP depletion was an early event and was not a consequence
of cell death.
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Figure 34. Effect of 3-BrOP and BCNU on energy metabolism in glioblastoma
stem cells. (A) Inhibition of lactate production in GSC11 cells by the indicated
concentrations of BCNU and 3-BrOP (3 h, hypoxia). *, P<0.05; ***, P<0.001. (B)
ATP depletion in GSC11 cells by the indicated concentrations of BCNU and 3-BrOP
for 3 h under hypoxia. (C) ATP depletion in GSC11 cells by the indicated
concentrations of BCNU and 3-BrOP for 6 h under hypoxia. (D) ATP depletion in
GSC23 cells by the indicated concentrations of BCNU and 3-BrOP for 3 h under
hypoxia. (E) Viability of GSC11 cells after incubation with 3-BrOP and BCNU for 3
h or 6 h under hypoxic conditions. Cell viability was measured by annexin-V/PI
double staining followed by flow cytometric analysis.
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Figure 35. Effect of 3-BrOP and TMZ on ATP generation in glioblastoma stem
cells. ATP generation in GSC11 cells by the indicated concentrations of BCNU and
TMZ for 3 hours (A) or 6 hours (B) under hypoxia. ATP generation in GSC23 cells
by the indicated concentrations of BCNU and TMZ for 3 hours (C) or 6 hours (D)
under hypoxia.
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Inhibition of GAPDH enzyme activity by BCNU and 3-BrOP
The observation that BCNU but not TMZ was able to potentiate the ability of 3BrOP to deplete ATP led us to speculate that BCNU might have certain unique mechanism
of action different from TMZ. This synergistic killing effect is a unique functional
characteristic of BCNU. Since BCNU is known to inhibit glutathione reductase by
alkylating its thiolate-active site (189), we speculated that it is possible that this compound
might inhibit the glycolytic enzyme GAPDH, which also has potential thiolate-active site for
alkylation by BCNU. To test this possibility, we assessed the GAPDH activity of GSCs after
treatment with BCNU and 3-BrOP alone and in combination for 30 minutes, and the protein
lysates were subjected to the assay for GAPDH activity. Interestingly, treatment with both 3BrOP and BCNU alone inhibited GAPDH activity by about 60% (Figure 36A), and
treatment with the combination of the two inhibited GAPDH activity by almost 80%, which
may explain why ATP was depleted dramatically in the combination setting. We further
confirmed inhibition of purified GAPDH by BCNU and 3-BrOP at various concentrations
using an in vitro enzymatic assay. The concentrations of BCNU and 3-BrOP required to
inhibit the purified GAPDH activity by 50% were about 200 µM and 10 µM, respectively
(Figure 36B-C). Incubation of purified GAPDH with the combination of BCNU and 3-BrOP
in vitro resulted in further inhibition of GAPDH activity (Figure 36D).
Similar to previous studies reported by Pereira da Silva’s group(86), we found that
hexokinase II is not a prefererd target of 3-BrOP in GSCs. Specifically, we observed that the
hexokinase II activity in GSC11 cells treated with 3-BrOP and BCNU at the same
concentrations used in our GAPDH activity assay was not effectively inhibited. (Figure 36E).
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We performed an in vitro enzymatic assay using purified hexokinase II and confirmed that
the same concentrations of 3-BrOP as those used in our GAPDH activity assay could not
effectively inhibit hexokinse activity and that concentrations as high as 300µM could inhibit
it by only 20% (Figure 36F). We observed no significant differences in the inhibition of
purified hexokinase activity in groups of GSCs incubated with BCNU and 3-BrOP alone or
in combination at different concentrations in vitro (data not shown).
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Figure 36. Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by
BCNU and 3-BrOP. (A) Effect of BCNU (BC) and 3-BrOP (Br) on GAPDH enzyme
activity in GSC11 cells. Cells were first incubated with the indicated concentrations of
BCNU or 3-BrOP for 30 min, and protein extracts were prepared for analysis of
GAPDH activity without further addition of the compounds in vitro. (B) Inhibition of
purified GAPDH enzyme by BCNU in vitro. (C) Inhibition of purified GAPDH
enzyme by 3-BrOP in vitro. (D) Inhibition of purified GAPDH enzyme by combination
of BCNU and 3-BrOP in vitro. (E) Hexokinase II activity of GSC11 cells after 30min
treatment with indicated concentrations of BCNU, 3-BrOP alone and combinations. (F)
Enzymatic activity inhibition of purified hexokinase II after 30min in-vitro incubation
with serial concentrations of 3-BrOP.
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3-BrOP impairs the ability of GSCs to repair BCNU-induced DNA damage
BCNU can cause DNA damage by formation of DNA monoadducts and also cause
inter-strand cross-links and double-strand breaks (DSBs) in DNA (190, 191). DSBs are
repaired in mammalian cells by nonhomologous end-joining and homologous recombination
repair after DNA damage (192), in which γH2AX formation is a rapid, sensitive cellular
response to the presence of DSBs (193). Since ATP is required for H2AX phosphorylation
and the subsequent complicated DNA repair process, we hypothesized that dramatic
depletion of the ATP pool in GSCs could compromise the DNA-repair process, rendering
GSCs unable to undergo DNA replication and ultimately leading to cell death. Using a
comet assay, we observed that treatment with BCNU alone or combination with 3-BrOP for
6 hours caused severe DNA damage in GSCs, resulting in the appearance of broken DNA as
the comet tails after single cell electrophoresis (Figure 37A). In GSCs treated with BCNU
alone, the DNA damage could be repaired 3-6 hours after the removal of BCNU, as
evidenced by the disappearance or reduction of the DNA tails (Figure 37A-B). However, the
GSCs were unable to repair the DNA damage in GSCs treated with the combination of
BCNU and 3-BrOP, as the DNA tails persisted after drug removal and the cells were
incubated in fresh medium (Figure 37A). In fact, the percentage of DNA in the tails
increased from 50% to 60% after 3-hour recovery and to more than 80% after 6-hour
recovery in GSCs treated with the drug combination (Figure 37B). Using flow cytometry,
we confirmed that the cell death in the combination treatment setting was irreversible even
after 18 hours of recovery in fresh medium (Figure 37C).
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Figure 37. 3-BrOP inhibits the repair of BCNU-induced DNA damage. (A) Comet
assay of DNA damage in GSC11 cells treated with BCNU, 3-BrOP, or their
combination. Cells were treated with the indicated concentrations of compounds for 6
hours, and then either immediately processed for comet assay or cultured in drug-free
medium for additional 3-6 hours for potential DNA repair. The bright green dots
represent the positions of cellular nuclei; the “tail” length and intensity and on the right
side of each nucleus represent the degree of DNA strand breaks eluted out from the
cell during electrophoresis. (B) Quantification of DNA damage in GSC11 cells treated
with or without BCNU and 3-BrOp as indicated. At least 30 cells in each sample were
quantitatively analyzed for % of DNA tail that eluted from the cellular nuclei. *,
P<0.05; **, P<0.01; ***, P<0.001. (C)Flow cytometric analysis (annexin-V/PI
staining) was also used to measure cell death at 24 h (18 h after drug removal).
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γH2AX is a commonly used marker for DNA DSB repair. Immediately after
formation of DSBs, the MRN complex (MRE11, RAD50, and NBS1) binds to broken DNA
ends and recruits active ATM, ATR, and/or DNA-PK, resulting in phosphorylation of the
subtype of histone H2A, called H2A, in the position of Ser 139 (γH2AX) and initiation of
the DNA-repair process (194), and dephosphorylation and removal of γH2AX in the cancer
cells has been shown to be a significant step toward turning off the DNA damage response
(195). In our study, we observed that when GSCs were incubated with BCNU for 4 hours,
both single-agent and combination treatment induced a large increase in γH2AX. When we
continuously treated GSCs for 6 hours, we observed that the DNA damage and active repair
were ongoing in the BCNU-alone group, whereas it was almost turned off with
dephosphorylation of H2AX in the combination group. As shown in Figure 38, the blotting
of γH2AX decreased. This was consistent with our results above indicating that maximum
ATP pool drainage in GSCs occurred after 6 hours of treatment with the combination of 3BrOP and BCNU.
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Figure 38. Effect of 3-BrOP and BCNU on H2AX phosphorylation. Western
blot analysis of γH2AX and total H2AX protein in GSC11 cells treated with the
indicated compounds for 2, 4 or 6 hours. BC, BCNU; Br, 3-BrOP.

115

3-BrOP and BCNU decrease tumorigenicity in vivo.
Since we observed that the combination of 3-BrOP and BCNU completely abolished
the ability of GSCs to form neurospheres in vitro, we further tested the effect of 3-BrOP and
BCNU on tumorigenicity in vivo by inoculating the cells into mice brain in cooperation with
Dr Xiao-nan Li’s lab. GSC11 cells were grown in serum-free medium and treated with PBS
(control), 20µM of 3-BrOP, 20µM of BCNU and the combination of 3-BrOP and BCNU for
6 hours. The same amount of cells was inoculated into mice brain. All mice in control, 3BrOP or BCNU group died. But only two out of five mice in the group treated with 20µM 3BrOP and 20µM BCNU had died (Figure 39). The survival curve showed that the mice in
the combination group live significantly longer than the control group (p=0.0027) and the
BCNU group (p=0.012).

Figure 39. Effect of 3-BrOP and BCNU on mice survival. GSC11 cells were
treated with PBS (control), 20µM of 3-BrOP, 20µM of BCNU and the combination of
3-BrOP and BCNU for 6 hours and inoculated orthotopically into mice.
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CHAPTER 6
DISSCUSSION
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Glioblastoma stem cells are held to be responsible for tumor initiation, progression
and recurrence due to resistance to treatments. Therefore, an improved understanding of the
mechanisms how GSCs maintain their stemness is crucial for designing new therapeutic
strategies for targeting GSCs. This study provided mechanistic and functional evidence that
mitochondrial ROS is important in triggering GSCs aberrant differentiation and GSCs rely
more on glycolytic metabolism than bulk tumor cells. By treating GSCs with a glycolytic
inhibitor 3-BrOP and a standard chemotherapeutic agent, BCNU, we identified a novel
therapeutic strategy to kill the GSCs that are resistant to conventional drug.
ROS trigger GSC aberrant differentiation
It has been known for some time that cancer stem cells, similar to normal stem cells,
require certain tissue microenvironment to maintain their stemness (76, 196), and exposure
of stem cells to serum in vitro usually induces differentiation with a loss of self-renewal
capacity (94). However, the specific serum factors that induce differentiation and the
underlying mechanisms remain unclear. Our study revealed a ROS-mediated mechanism by
which serum induces GSC differentiation. We found that exposure of glioblastoma stem
cells to serum activated mitochondrial respiration, leading to an increase of oxygen
consumption and an increase in generation of mitochondrial O2-, which induced the
expression of SOD2 to convert O2- to H2O2. Owing to its relatively long half-life and ability
to diffuse across biological membranes, H2O2 has been considered as a second messenger
that mediates redox-sensitive signaling in cellular response to growth factors (197, 198).
The ability of H2O2 to cause oxidation of protein thiol via catalytic cysteine can alter the
function of the target proteins, and thus provides a mechanism for redox signaling (198).
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Since superoxide has an extremely short half-life and cannot pass the mitochondrial
membranes, the increased O2- within the mitochondria could not directly function as a
second messenger to affect the nuclear gene expression. As such, conversion of the
mitochondrial O2- to H2O2 by SOD2 seems important to relay the redox signal from
mitochondria to cytosol and nucleus during serum-induced differentiation of GSCs. The
upregulation of SOD2 in serum-treated GSCs would facilitate the conversion of O2- to H2O2.
Previous studies suggest that breast CSCs retain low levels of ROS, which lead to
less DNA damage and contribute to their resistance to radiation (46). Drug-tolerant stemlike breast cancer cells show lower levels of ROS and an increase in antioxidant enzymes
compared with the parental untreated cells (199). Additionally, tumor sample tissues from
patients pre-treated with chemotherapy drugs also show lower levels of ROS and enhanced
expression of superoxide dismutase compared with the tumor tissues from patients that don’t
receive any chemotherapy (199). Our study confirmed that CSCs maintain a low redox
status by comparing the GSCs to their aberrant differentiated counterparts. Under serum
induction, the GSCs upregulate their mitochondrial ETC function, which triggers the
transition of mitochondria from low function into activation and results in an increase of
mitochondrial ROS. These results may explain the phenomenon that CSCs have lower ROS
than non-stem cancer cells. The correlation between mitochondrial function and the
regulation of CSCs has been found in glioma. Inhibition of ETC by a complex I inhibitor
rotenone or long-term treatment with low doses of ethidium bromide to deplete
mitochondrial DNA (ρ0 cells) enriched CD133+ cells (83). The ρ0 cells lacking a functional
electron transport chain developed enhanced anchorage-independent growth and increased
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invasion phenotypes (83). However, our results showed that the mitochondrial ROS instead
of ETC itself is important in triggering serum-induced aberrant differentiation.
Although the ability of ROS to induce stem cell differentiation has been noticed in
some experimental systems (200), the exact mechanisms remain unclear. Our study suggests
that the down regulation of SOX2, Olig2, and the Notch-related molecules by ROS might be
a potential mechanism. Since SOX2, Olig2, and the Notch pathway are involved in
promoting neural stem cells function (201, 202), down regulation of these genes would lead
to a loss of stemness and promote differentiation. It is possible that the expression of SOX2,
Olig2, and the Notch-related molecules are regulated via a redox-sensitive mechanism, with
ROS being a negative regulator. The ability of exogenous antioxidant NAC to prevent the
decreased expression of these genes and to block the serum-induced differentiation
phenotype supports this notion. CSCs may maintain their ROS at a low status through
expressing some special molecules. For instance, CD44, a widely used CSC marker, was
recently found to contribute to ROS defense by stabilizing a glutamate-cystine transporter,
xCT, and promoting the synthesis of GSH (154).
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The effects of ROS on the GSC aberrant differentiation are likely mediated by NFĸB
NFĸB signaling pathway plays a crucial role in cancer development and progression
(203). It can either promote or inhibit carcinogenesis, depending on the cell type in which it
acts. The NFκB transcription factors are assembled through dimerization of five subunits,
namely p65 (RelA), v-rel reticuloendotheliosis viral oncogene homolog B (RelB), c-Rel,
p50 (NFκB1) and p52(NFκB2) (204). The five subunits share the same DNA binding
domain, Rel homology domain. Prior to cell stimulation, the majority of NFκB subunits are
kept in the cytoplasm by a family of proteins called IκBs that prevent NFκB’s binding to
DNA. Activated IκB kinase (IKK) phosphorylates IκBs and triggers their degradation and
the nucleus translocation of NFκB. NFĸB signaling pathway is often activated by ROS
through IĸB or IKK phosphorylation (205). This study found that serum could cause the
activation of NFκB which could be blocked by the antioxidant NAC. These results suggest
that the activation of NFĸB in the serum-induced cells is probably caused by the ROS
increase (Figure 40). It’s worth noting that deletion of NFĸBIA which encodes the NFĸB
inhibitor IĸBα is a frequent oncogenic event in GBM (206). NFĸB activation is also
involved in the formation of breast cancer stem cells in response to transient activation of
Src oncoprotein (207). Our observation that NFĸB is activated in glioblastoma-initiating
cells after induction of differentiation by FBS was also confirmed by Nogueira et al (208).
Since NFĸB plays a crucial role not only in neural stem cell differentiation but also in brain
cancer stem cells (208, 209), it is probably the signaling pathway which connects seruminduced ROS increase with the aberrant differentiation of glioblastoma stem cells. We have
found a selective IKK1 and IKK2 inhibitor BMS-345541 can protect the decrease of a stem
cell marker CD133 and prevent the increase of a differentiation marker ANXA1 (210).
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However, the underlying mechanism of how NFĸB pathway affects GSC differentiation still
needs to be further clarified.
Interestingly, although the serum induction caused the aberrant differentiation of
GSCs and the decreases of stem cell markers-CD133, SOX2 and Olig2, it led to an increase
of tumorigenicity and a reduction of survival in mice. These results seem to jeopardize the
conventional theory of cancer stem cells which holds that only CSCs have the ability to form
tumor and they will lose the tumorigenicity once going to differentiation. It has been
postulated that CSCs preferentially transplant disease and contribute disproportionately to
tumor growth compared to more differentiated cells (211). However, a recent study found
that tumor cell self-renewal doesn’t predict tumor growth potential (211). Glioma cells with
low self-renewal capacity were more tumorigenic and generate tumor more rapidly than
cells with high self-renewal capacity (211). Our results had similar observations and may
provide a mechanistic interpretation of this phenomenon. The role of NFĸB pathway in
normal stem cell proliferation has been identified. NFĸB is stimulated during human
embryonic stem cell (hESC) differentiation and inhibition of NFĸB leads to a reduction of
hESC proliferation and suppression of differentiation toward all primitive extraembryonic
and embryonic lineages with the exception of primitive ectoderm and ectodermal lineages
(204). Whether the NFĸB signaling has a similar role in CSCs still needs to be elucidated.
If NFĸB is the crucial pathway in promoting CSCs proliferation and disease
progression, targeting NFĸB will be effective in eradicating the CSCs. Several studies have
shown that targeting NFĸB pathway can be effective in killing CSCs (212-214). Inhibition
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of NFĸB through using compounds including niclosamide and disulfiram can kill AML stem
cells and breast CSCs (212, 214).

Figure 40. ROS mediates serum-induced aberrant differentiation. GSCs have
low mitochondrial function and rely more on glycolysis for energy production.
Serum factors trigger the activation of mitochondrial function and electron transport
chain, which leads to the ROS increase. The upregulation of ROS causes NFκB
activation and results in cell proliferation and tumor progression.
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Potential therapeutic importance of inducing differentiation in GSCs
Cancer stem cells or tumor-initiating cells play a major role in drug resistance and
disease recurrence owing to their high self-renewal capacity and the ability to repair DNA
damage and export cytotoxic compounds (44, 45). The unique biological properties of
cancer stem cells render them difficult to be eliminated in vivo using conventional therapies.
The recognition of the important role of cancer stem cells in drug resistance has prompted
recent search for new means to overcome this significant problem in cancer treatment.
Because the stemness of cancer cells is critical for cancer development and disease
recurrence, induction of cancer stem cell differentiation has been considered as a potential
therapeutic strategy (215, 216). For example, all-trans-retinoic acid (ATRA) and arsenic
trioxide have been shown to induce differentiation in acute promyelocytic leukemia and
turned out to be effective in the treatment of this malignancy (217, 218). ATRA can induce
differentiation and reduce tumorigenicity in stem-like glioma cells (219). Thus,
identification of the key factors that induce cancer stem cells differentiation and elucidation
of the underlying mechanisms could have significant implications in developing novel
therapeutic strategies to impact CSCs and to improve the outcomes of cancer treatment. Our
study suggests that the cellular redox status may profoundly affect the fates of glioblastoma
stem cells, and that modulation of mitochondrial function and ROS generation may be an
effective way to impact CSCs. As such, induction of cancer stem cell differentiation by
ROS-mediated mechanisms seems to add a new mean to the “radical” therapeutic
approaches to cancer therapy (30).
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The combination of 3-BrOP and BCNU exhibits a striking synergistic killing effect in
GSCs.
In the present study, we observed that GSCs had low mitochondrial respiration.
Glycolysis serves as the major energy source for maintenance of CSC metabolism, survival,
and self-renewal. An effective agent that targets glycolysis can achieve the goal of
eliminating CSCs. A glycolytic inhibitor 3-BrOP shows its efficacy in killing the drug
resistant GSCs. We postulated that ATP depletion induced by glycolytic inhibition could
cause a severe energy crisis, which could lead to a severe compromise of GSC’s ability to
repair DNA damage induced by chemotherapeutic agents (Figure 41). However, it seems
that it is necessary to deplete ATP to certain level in order to effectively compromise the
ability of DNA repair. In GSCs, this severe ATP depletion could be efficiently achieved by
combination of 3-BrOP with BCNU, but not with TMZ. This is due to the ability of BCNU
and 3-BrOP to inhibit GAPDH activity in a synergistic fashion. This finding raises a
potential for use of this drug combination to eliminate GSCs and overcome the resistance of
glioblastoma to chemotherapeutic drugs, especially under hypoxic conditions. Almost all
GSCs were effectively killed by this combination in 24 hours and a short term exposure to
this drug combination that has not shown killing effect in vitro could already reduce GSCs’
tumorigenicity and prolong survival in mice.
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Figure 41. The combination of 3-BrOP and BCNU induces cell death. On one
hand, 3-BrOP can cause the decrease of ATP by inhibiting glycolysis and BCNU can
induce further decrease of ATP probably through inhibiting GAPDH activity. On the
other hand, BCNU causes DNA damage which needs ATP for repairing. While the
ATP crisis makes the DNA repair system nonfunctional and results in constant DNA
damage and cell death.
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Patients with glioblastoma multiforme, the most aggressive primary brain tumor,
have poor prognoses, and there have been only limited improvements of therapeutic
outcomes and patient overall survival over the past two decades, although multidisciplinary
therapies for this cancer are performed (220). GSCs seem to reside in the niches where the
cells are in hypoxic microenvironment, which contributes significantly to cancer
chemoresistance and radioresistance (221). Although an increase in drug dosage could
increase the effective drug concentration in the brain to kill more cancer cells, this may also
increase toxic side effect and thus limit its applications. Furthermore, GSCs may adapt
quickly to drug treatment by expressing increasing numbers of drug efflux pumps, DNA
repair proteins like O6-methylguanine-DNA methyltransferase, and antiapoptotic proteins.
In the case of BCNU, this compound has a very short half-life and the drug become
undetectable after 5 minutes of treatment (222). Also, BCNU penetration in the brain tissue
occurs over only a very short distance, approximately 2 mm from the ependymal surface
(223). Thus, achieving and maintaining effective high concentration of BCNU in the tumor
tissue is difficult. For effective and selective killing of cancer cells, especially CSCs,
determining the fundamental differences between cancer and normal cells is critically
important. For example, the cell energy metabolism pathway has emerged as a potential
candidate target for treatment of cancers. Multiple studies have confirmed that nutrient
metabolism in cancer cells may be different from that in normal cells. As first proposed by
Otto Warburg (157), cancer cells might rely more on glycolysis for metabolism and survival,
and the mitochondria in these cells were functionally aberrant.
The observation that BCNU inhibited GAPDH activity is a novel finding of this
study, although the primary pharmacological action of BCNU has been traditionally
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attributed to its nucleoprotein alkylation and inhibition of DNA synthesis and repair
mediated by its active chloroethyl moieties (224). BCNU may covalently inactivate GAPDH
activity by S-nitrosylation of cysteine thiols which are important for disulfide formation.
Although GAPDH activity can be inhibited by 50% with 200µM BCNU alone, we observed
only a moderate depletion of ATP after 6 hours of treatment with BCNU at this
concentration. A possible explanation for the small ATP decrease could be that inhibition of
glycolysis by BCNU might have been compensated by mitochondrial oxidative
phosphorylation. This is in contrast to 3-BrOP, which seems to inhibit both glycolysis and
mitochondrial respiration to a certain degree (86, 225, 226). This might explain why 3-BrOP
could deplete ATP more efficiently than BCNU when each compound was used alone.
Although hexokinase II has been considered a major target of 3-BrPA (174, 227-229), a
recent study using HepG2 cells suggested that this compound might inhibit GAPDH activity
more effectively (86). It is possible that the synergistic combination effect of 3-BrOP and
BCNU observed in the present study might be due, at least in part, to the fact that both
compounds inhibit the same glycolytic enzyme GAPDH. The combination of sub-toxic
concentrations of 3-BrOP and BCNU seems to be an optimum way to inhibit GAPDH and to
achieve effective killing of GSCs with low toxicity to normal cells. This is largely due to the
unique mechanisms of action of each compound and the biological properties of GSCs,
which are highly dependent on glycolysis and thus sensitive to such metabolic intervention.
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Future Perspectives
Many questions regarding the mechanisms of how NFĸB pathway leads to seruminduced GSC activation and whether the combination of 3-BrOP and BCNU is effective in
vivo remain. We showed that serum could induce the activation of NFĸB pathway and NAC
was able to inhibit this activation. It is important to test whether the NFĸB pathway is
crucial for the serum-induced GSC activation. Ideally, key components of NFĸB pathway
would be knocked down in GSCs and tumorigenicity of the cells would be tested to confirm
that the NFĸB pathway trigger the GSC activation. Moreover, activators such as interleukin1 and TNFα would be used to activate the NFĸB in GSCs and their effects on tumorigenicity
and malignancy would be assayed. Potentially, besides the NFĸB activation, the metabolic
alteration caused by serum induction is also important in mediating GSC activation. ATP
generation and metabolite intermediates as well as cell cycle change promote the malignant
transition of GSCs. Alternatively; other pathways like JNK also play some role in GSC
activation. These possibilities should be explored in further detail.
Another important question is whether the combination of 3-BrOP and BCNU is
effective in vivo. Our results implicate therapeutic potential of the combination treatment.
However, whether 3-BrOP can pass the blood brain barrier remains unknown. Implantable
pump for drug delivery to the brain would be utilized to study the effect of 3-BrOP and
BCNU combination in glioblastoma xenografts. The toxicities of this combination need to
be investigated.
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Conclusion
My study demonstrates that GSCs have low mitochondrial function and depend on
glycolysis for energy production. Activation of mitochondrial by factors like serum causes
ROS increase which leads to the induction of differentiation (Figure 42). The transition from
glycolysis to oxidative phosphorylation moves GSCs into an intermediate stage and causes
tumor proliferation and progression. Targeting the glycolytic metabolism with 3-BrOP and
BCNU can achieve a striking killing effect in GSCs.

Figure 42. A schematic model representing the role of metabolism change in tumor
development.
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